CA2198357C - Electrotransport system with remote telemetry link - Google Patents
Electrotransport system with remote telemetry link Download PDFInfo
- Publication number
- CA2198357C CA2198357C CA002198357A CA2198357A CA2198357C CA 2198357 C CA2198357 C CA 2198357C CA 002198357 A CA002198357 A CA 002198357A CA 2198357 A CA2198357 A CA 2198357A CA 2198357 C CA2198357 C CA 2198357C
- Authority
- CA
- Canada
- Prior art keywords
- electrotransport
- control unit
- delivery
- radiated energy
- signal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
- A61B5/1451—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
- A61B5/14514—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
Abstract
An electrotransport system (20) for delivering a therapeutic agent (36) through a body surface (40) (e.g., skin) of a patient includes a pair of electrodes (34, 38) for contacting the body surface, at least one of which contains the therapeutic agent (36). The system (20) is physically separated into a control unit (22) and a delivery unit (24) connected by a radiated energy signal-based telemetry link. The telemetry link may be radio frequency, ultrasonic, optical, infrared or inductively coupled. Signals from the control unit may be transmitted to the delivery unit by the telemetry link, or vice versa. The delivery unit may control electrotransport current on the signal transmitted.
The radiated energy signal may be encoded to improve immunity to extrinsic interference. The delivery unit (24) may be configured with sensor means for detecting a condition such as a body or system parameter reaching some predetermined limit. The delivery unit (24) may also have an additional telemetry link connecting to the control unit (22) for transmitting the system or body status condition to the control unit. Visual or audio indicators may be provided on the control unit (22) for indication of system or body status conditions detected and transmitted by the delivery unit (24).
The radiated energy signal may be encoded to improve immunity to extrinsic interference. The delivery unit (24) may be configured with sensor means for detecting a condition such as a body or system parameter reaching some predetermined limit. The delivery unit (24) may also have an additional telemetry link connecting to the control unit (22) for transmitting the system or body status condition to the control unit. Visual or audio indicators may be provided on the control unit (22) for indication of system or body status conditions detected and transmitted by the delivery unit (24).
Description
ri 2 ~ ~ '~ ~ J ~' / PCTIUS95113218 ELECTROTRANSPORT SYSTEM WITH REMOTE TELEMETRY LINK
This invention relates to electrotransport devices for delivering a therapeutic agent leg, a drug), which devices have telemetry means for communicating between agent delivery means and remote controlling means for controlling and receiving parameters of therapeutic agent electrotransport s delivery.
The term "electrotransport" as used herein refers generally to the ~o delivery of an agent leg, a drug) through a membrane, such as skin, mucous membrane, or nails. The delivery is induced or aided by application of an electrical potential. For example, a beneficial therapeutic agent may be introduced into the systemic circulation of a human body by electrotransport delivery through the skin. A widely used electrotransport process, ~s electromigration (also called iontophoresis), involves the electrically induced transport of charged ions. Another type of electrotransport, electroosmosis, involves the flow of a liquid, which liquid contains the agent to be delivered, under the influence of an electric field. Still another type of electrotransport process, electroporation, involves the formation of transiently-existing pores zo in a biological membrane by the application of an electric field. An agent can be delivered through the pores either passively lie, without electrical assistance) or actively lie, under the influence of an electric potential).
However, in any given electrotransport process, more than one of these processes may be occurring simultaneously to a certain extent. Accordingly, zs the term "electrotransport", as used herein, should be given its broadest possible interpretation so that it includes the electrically induced or enhanced transport of at least one agent, which may be charged, uncharged, or a p,:..~-'~, '?
W096113302 L i y'~ .% .'.~ ~ PGTTUS95/1321$
mixture thereof, whatever the specifrc mechanism or mechanisms by which the agent actually is transported.
Electrotransport devices use at least two electrodes that are in s electrical contact with some portion of the skin, nails, mucous membrane, or other surface of the body. One electrode, commonly called the "donor" or "active" electrode, is the electrode from which the agent is delivered into the body. The other electrode, typically termed the "counter" or "return"
electrode, serves to close the electrical circuit through the body. For ,o example, if the agent to be delivered is positively charged, ie, a cation, then the anode is the active or donor electrode, while the cathode serves to complete the circuit. Alternatively, if an agent is negatively charged, ie, an anion, the cathode is the donor electrode. Additionally, both the anode and cathode may be considered donor electrodes if both anionic and is cationic agent ions, or if uncharged or neutrally charged agents, are to be delivered.
Furthermore, electrotransport delivery systems generally require at least one reserUOir or source of the agent to be delivered, which is typically zo in the form of a liquid solution or suspension. Examples of such donor reservoirs include a pouch or cavity, a porous sponge or pad, and a hydrophilic polymer or a gel matrix. Such donor reservoirs are electrically connected to, and positioned between, the anode or cathode and the body surface, to provide a fixed or renewable source of one or more agents or zs drugs. Electrotransport devices also have an electrical power source such as one or more batteries. Typically, one pole of the power source is electrically connected to the donor electrode, while the oppos'tte pole is electrically connected fo the counter electrode. In addition, some electrotransport devices have an electrical controller that controls the current 3o applied through the electrodes, thereby regulating the rate of agent delivery.
Furthermore, passive flux control membranes, adhesives for maintaining W096f13302 G ~ ~ ;~ "yf ' ' m3 PCTlCTS95/13218 device contact with a body surface, insulating members, and impermeable backing members are o#her op#ional components of an electrotransport device.
s All electrotransport agent delivery devices utilize an electrical circuit to electrically connect the power source leg, a battery) and the electrodes.
In very simple devices, such as those disclosed in Ariura et al US Patent 4,474,570, the "circuit" is merely an electrically conductive wire used to connect the battery to an electrode. Other devices use a variety of io electrical components to control the amplitude, polarity, timing, waveform shape, etc. of the electric current supplied by the power source.
See, for example, McNichols et al US Patent 5,047,007.
To date, commercial transdermal elec#rotransport drug delivery ~s devices leg, the Phoresor, sold by loured, Inc. of Salt Lake City, UT;
the Dupel lontophoresis System sold by Empi, Inc. of St. Paul, MN;
the Webster Sweat Inducer, model 3600, sold by Wescor, Inc. of Logan, UT) have generally utilized a desk-top electrical power supply unit and a pair of skin contacting electrodes. The donor electrode contains a drug solution zo while the counter electrode contains a solution of a bio-compatible electrolyte salt. The "satellite" electrodes are connected to the electrical power supply unit by long leg, 1-2 meters) electrically conductive wires or cables.
Examples of desk-top electrical power supply units which use "satellite"
electrode assemblies are disclosed in Jacobsen et al US Patent 4,141,359 z5 (see Figures 3 and 4); LaPrade US Patent 5,006,108 (see Figure 9); and Maurer et al US Patent 5,254,081 (see Figures 1 and 2). The power supply units in such devices have electrical controls for adjusting the amount of electrical current applied through the electrodes. The "satellite" electrodes are connected to the electrical power supply unit by long leg, 1-2 meters) so electrically conductive wires or cables. Wire connections are subject to disconnection, limit patient movement and mobility and can also be .,~a x ~ ~ M:
WO 96!13302 ~ '~ J ~ '~ ~ P47YUS95II321$
This invention relates to electrotransport devices for delivering a therapeutic agent leg, a drug), which devices have telemetry means for communicating between agent delivery means and remote controlling means for controlling and receiving parameters of therapeutic agent electrotransport s delivery.
The term "electrotransport" as used herein refers generally to the ~o delivery of an agent leg, a drug) through a membrane, such as skin, mucous membrane, or nails. The delivery is induced or aided by application of an electrical potential. For example, a beneficial therapeutic agent may be introduced into the systemic circulation of a human body by electrotransport delivery through the skin. A widely used electrotransport process, ~s electromigration (also called iontophoresis), involves the electrically induced transport of charged ions. Another type of electrotransport, electroosmosis, involves the flow of a liquid, which liquid contains the agent to be delivered, under the influence of an electric field. Still another type of electrotransport process, electroporation, involves the formation of transiently-existing pores zo in a biological membrane by the application of an electric field. An agent can be delivered through the pores either passively lie, without electrical assistance) or actively lie, under the influence of an electric potential).
However, in any given electrotransport process, more than one of these processes may be occurring simultaneously to a certain extent. Accordingly, zs the term "electrotransport", as used herein, should be given its broadest possible interpretation so that it includes the electrically induced or enhanced transport of at least one agent, which may be charged, uncharged, or a p,:..~-'~, '?
W096113302 L i y'~ .% .'.~ ~ PGTTUS95/1321$
mixture thereof, whatever the specifrc mechanism or mechanisms by which the agent actually is transported.
Electrotransport devices use at least two electrodes that are in s electrical contact with some portion of the skin, nails, mucous membrane, or other surface of the body. One electrode, commonly called the "donor" or "active" electrode, is the electrode from which the agent is delivered into the body. The other electrode, typically termed the "counter" or "return"
electrode, serves to close the electrical circuit through the body. For ,o example, if the agent to be delivered is positively charged, ie, a cation, then the anode is the active or donor electrode, while the cathode serves to complete the circuit. Alternatively, if an agent is negatively charged, ie, an anion, the cathode is the donor electrode. Additionally, both the anode and cathode may be considered donor electrodes if both anionic and is cationic agent ions, or if uncharged or neutrally charged agents, are to be delivered.
Furthermore, electrotransport delivery systems generally require at least one reserUOir or source of the agent to be delivered, which is typically zo in the form of a liquid solution or suspension. Examples of such donor reservoirs include a pouch or cavity, a porous sponge or pad, and a hydrophilic polymer or a gel matrix. Such donor reservoirs are electrically connected to, and positioned between, the anode or cathode and the body surface, to provide a fixed or renewable source of one or more agents or zs drugs. Electrotransport devices also have an electrical power source such as one or more batteries. Typically, one pole of the power source is electrically connected to the donor electrode, while the oppos'tte pole is electrically connected fo the counter electrode. In addition, some electrotransport devices have an electrical controller that controls the current 3o applied through the electrodes, thereby regulating the rate of agent delivery.
Furthermore, passive flux control membranes, adhesives for maintaining W096f13302 G ~ ~ ;~ "yf ' ' m3 PCTlCTS95/13218 device contact with a body surface, insulating members, and impermeable backing members are o#her op#ional components of an electrotransport device.
s All electrotransport agent delivery devices utilize an electrical circuit to electrically connect the power source leg, a battery) and the electrodes.
In very simple devices, such as those disclosed in Ariura et al US Patent 4,474,570, the "circuit" is merely an electrically conductive wire used to connect the battery to an electrode. Other devices use a variety of io electrical components to control the amplitude, polarity, timing, waveform shape, etc. of the electric current supplied by the power source.
See, for example, McNichols et al US Patent 5,047,007.
To date, commercial transdermal elec#rotransport drug delivery ~s devices leg, the Phoresor, sold by loured, Inc. of Salt Lake City, UT;
the Dupel lontophoresis System sold by Empi, Inc. of St. Paul, MN;
the Webster Sweat Inducer, model 3600, sold by Wescor, Inc. of Logan, UT) have generally utilized a desk-top electrical power supply unit and a pair of skin contacting electrodes. The donor electrode contains a drug solution zo while the counter electrode contains a solution of a bio-compatible electrolyte salt. The "satellite" electrodes are connected to the electrical power supply unit by long leg, 1-2 meters) electrically conductive wires or cables.
Examples of desk-top electrical power supply units which use "satellite"
electrode assemblies are disclosed in Jacobsen et al US Patent 4,141,359 z5 (see Figures 3 and 4); LaPrade US Patent 5,006,108 (see Figure 9); and Maurer et al US Patent 5,254,081 (see Figures 1 and 2). The power supply units in such devices have electrical controls for adjusting the amount of electrical current applied through the electrodes. The "satellite" electrodes are connected to the electrical power supply unit by long leg, 1-2 meters) so electrically conductive wires or cables. Wire connections are subject to disconnection, limit patient movement and mobility and can also be .,~a x ~ ~ M:
WO 96!13302 ~ '~ J ~ '~ ~ P47YUS95II321$
uncomfortable. The wires connecting the power supply unit to the electrodes limits their separation to the length of the wires provided. It would be an advantage to retain the benefits of a remote means for controlling the operation of an elecfrotransport delivery device wom by a patient s leg, in a hospital ward) without the disadvantages of intervening wires.
More recently, small self contained electrotranspor# delivery devices adapted to be wom on the skin, sometimes unobtrusively under clothing, for extended periods of time have been proposed. The electrical components in io such miniaturized electratransport drug delivery devices are also preferably miniaturized, and may be either integrated circuits lie, microchips) or small printed circuits. Electronic components, such as batteries, resistors, pulse generators, capacitors, etc., are electrically connected to form an electronic circuit that controls the amplitude, polarity, timing, waveform shape, etc. of 3s the electric current supplied by the power source. Such small self contained electrotransport delivery devices are disclosed far example in Topper US Patent 5,224,921; Siba(is et al US Patent 5,224,928 and tiaynes et al US Patent 5,246,418.
z~ Wrth regard to providing electrical current to electrotransport electrodes, Henley U.S. Patent 5,1fi0,316 discloses a generator driving a primary isolated current loop. The current loop feeds current to individual channels in a wide area, multi-channel electrode via a plurality of individual secondary current Poops. The isolated primary current loop is disposed in zs adjacent, but insulated alignment with the individual secondary current loops far close inductive coupling. There is no power source for the electrotransport currents except the coupled current from the isolated primary current loop. The controls and switches for the isolated primary current loop are contained iri a control box connected to the primary current loop. The so current loops in Henley must be very closely coupled to have efficient transfer of current. If the current loop were physically separated by a WO 96!13302 ~ ~ ~ PCT/ITS95l13218 significant distance, say several feet, from the individual current loops, the control of the electrotransport current, and hence the rate of electrotransport drug delivery, would vary considerably.
s One concern, particularly with small self-contained electrotransport delivery devices that are adapted to be wom on the body andlor under clothing, is the diffiiculty and inconvenience of using controls or reading indicators on the device. This is also a concern (ie, from the standpoint of viewing the electrotransport delivery device or to manipulate controls ~o thereon) when the electrotransport device is worn on an inconvenient area of the body, such as the back, the upper outer arm, and the like. Also, whereas it is convenient to have very small delivery units that are unobtrusive, it is a disadvantage if the delivery unit has controls that are too small to be effectively manipulated, or indicators (eg, LED's) that are too is small to be clearly seen, by a substantial portion of the population (eg, the elderly).
It may be desired, for example, to have a start button on the electrotransport device that initiates drug delivery on demand of the patient.
zo Wi#h a small, self-contained unit, the placement of the unit on the patient's body is usually limited to a body location that the patient can both see and reach. The limited location option may interfere with the efficacy of the therapy. Thus, in certain situations it would be an advantage to separate the controls for controlling the operation of the electrotransport delivery device zs from the device itself.
It may also be desired to obtain some delivery system information for the benefit of the user or a medical attendant. Examples of such delivery system information include the dosing history, amount of drug remaining in ao the system to be delivered, battery life, whether the system is presently in a "delivery" mode or an "off' mode, etc. There have been proposals to WO96113302 ~w~ ~"~ A~ ~ '°~, ~ PCTIUS9S113218 incorporate patient monitoring features into electrotransport drug delivery devices. One example is blood glucose monitoring for an electrotransport insulin delivery device. Thus, if the sensed glucose levels become too high, the glucose level indicator would instruct the patient to activate the device to deliver insulin. Other types of patient information besides blood glucose levels could also be sensed and displayed on an electrotransport device indicator far the benefit of the patient ar a medical technician. For example, application of therapeutic drugs, whether by electrotransport or more traditional leg, oral) dosing, can sometimes cause unwanted reactions in ~a certain patients. These reactions can take many farms, including respiratory depression, change in heart rate, change in body temperature, sweating, shaking and the like. It would be advantageous to provide this system and/or patient information to a remote indicator so that the information may be read at a remote location leg, at a central nurse's station in a ~s hospital ward). This would enable a nurse or attendant to take action without having to check the delivery device worn by the patient, remove the patient's clothing ar otherwise disturb the patient:
It would clearly be desirable to have electrotransport delivery systems za available in a configuration with the controls and indicators mounted on a control unit that is remote from the delivery unit. The present invention provides the needed improvement without diminishing the intended therapeutic efficacy of the device or the therapeutic substance to be administered.
There is a need for an electrotransport device for administering a drug through a body surface leg, skin), having complete freedom of placement of 3o delivery electrodes, without compromising the ability of the patient ar a medical technician to control the operation of the device.
RTO 96!13302 ~. i ~% ~ ..i' .j ~' PCTlUS95113218 There is also a need for an electrotransport device having improved access to controls and status indicators independent of the location of the delivery device on a patient's body.
s There is a furkher need far a small electrotransport delivery device adapted to be worn by the patient unobtrusively (eg, under clothing ) for which the control and display features are not limited by the size of the device.
,o The present invention is directed to an electrotransport system for delivering a therapeutic agent through the skin of a patient, that satisfies the needs described above. The electrotransport system is comprised of a control unit and a delivery unit, which two units are remote from one another and communicate with one another using telemetry. The delivery unit is ~s adapted for mounting on the body surface (eg, skin) of a patient. The delivery unit includes a pair of electrodes, at least one of which is a "donor"
electrode containing the therapeutic agent (eg, a drug) to be delivered through the body surface (eg, skin). The delivery unit also includes a source of electrical power (eg, one or more batteries) which is electrically zo connectable to the electrodes in order to apply an electrotransport current through the electrodes and the patient. The system is characterized by a telemetry communication link between the delivery and control units whereby the units communicate by means of a radiated energy signal transmitter means and a radiated energy signal receiver means.
zs In a preferred embodiment, the control unit communicates with the delivery unit in order to control the electrotransport current applied to the patient, and thereby control the delivery of the therapeutic agent to the patient. In a more preferred embodiment, the delivery unit includes a so receiver means adapted for receiving a radiated energy signal which is transmitted by the control unit and providing a control signal responsive WO9b1t3302 "~ ~ »~'~ ~ ~.y~ PCT/OB95Ii32t8 thereto. The delivery unit also includes a current control means adapted to control {eg, control the initiation, interruption, magnifude, polarity, waveform shape, pulsing frequency, and/or duty cycle) the electrotransport current applied. The current control means is responsive to the control signal from s the receiver means. The control unit, which is remote from the delivery unit wom by the patient, preferably includes a transmitter means. The transmitter means is responsive to an input signal, for example, a preprogrammed and/or a manually selected input signal chosen by the operator leg, the patient or a medical technician). Upon receiving the input signal, the ,o transmitter means Transmits a radiated energy signaC {eg, an infrared signal, a radio frequency signal, or an ultrasonic signal) to the receiver means in the delivery unit, whereby the electrotransport current applied by the delivery unit is controlled by the input signal to the remote control unit.
~s The distance separating The control unit from the delivery unit is limited only by the strength of the transmitted radiated energy signal Tram the transmitter means, the signal-to-noise ratio of the receiver means and the radiated energy modulation scheme selected for the particular implementation. The distance can range from quite small 20 leg, several centimeters) to very large leg, hundreds of kilometers).
The control unit may be a small, lightweight unit leg, a wand or hand held unit) and optionally may be mounted on an easily accessible part leg, the wrist or lower arm) of the patient's body, Alternatively, the control zs unit may be a larger unit leg, desk size) with a more powerful transmitter adapted to operate within, eg, several hundred meters of the delivery unit.
In such caws, the control unit may be operated from the patient's bedside ar from a centralizetf nursing station in a hospital ward WO 96113302 ~ ~ ~~~ ~~ ..? s_t ! PCT/US95li32i8 The control unit may optionally include a plurality of manually operated switches adapted to provide a plurality of signal inputs to the control unit for transmitting a plurality of signals to the delivery unit.
The electrotransport control unit may also optionally include a microprocessor having a plurality of inputs connected suitably to the plurality of switches. The microprocessor has an output connected to the transmitter for controlling the radiated energy signal to be transmitted. The microprocessor may have a plurality of stored programs for providing a io corresponding plurality of control signals. The operator selects one of the stored programs, eg, by selecting one of a plurality of manually operated switches in order to cause the delivery unit to deliver an electrotransport current of predetermined amplitude, timing, etc, which corresponds to the operator's selection.
The telemetry link may be provided by one of a number of radiated energy transmitting and receiving means. In a preferred embodiment, the radiated energy is radio frequency (RF) radiated energy over a range of frequencies of between about 1 MHz to about 1000 MHz. The radio zo frequency energy may be modulated by amplitude modulation, frequency modulation, frequency shift keying, or phase shift keying. Alternatively, the radiated energy may be in the form of ultrasonic radiant energy, optical radiant energy or by the radiant energy of electromagnetic induction.
z5 The electrotransport telemetry may include a coding and decoding means for coding the transmitted signals in a predetermined security code.
Coding the transmifted signal provides additional security against falsely initiating agent delivery due to unwanted signals such as extrinsic radiant energy interference.
wo vsras3o2 ~. pc~rrUSVSnsms 1 d~"
~1~~CJ~
The electrotransport telemetry system of this invention may include a sensor means mounted in the delivery unit for sensing a predetermined patient body parameter condition, such as breathing rate, blood glucose concentration, skin resistance, body motion, muscle movement s (eg, contraction); tissue oxygen content, tissue carbon dioxide content, body temperature, heart rate, sweat response or the like. The sensor means may provide a sense signal to a return radiated energy transmitter means for transmitting a return radiated energy signal to the control unit. The control unit may have a corresponding receiver for receiving the return radiated ~o energy signal from the delivery unit. The control unit may include an indicator for displaying the sensed parameter condition by any type of conventional display means including LED, LCD display, audio annunciator ar the like and in the case of a larger size control unit the indicator for displaying the sensed parameter may be a cathode ray tube, or other type of ,s video screen, a printer or the like. Alternatively, the delivery unit may have a sensor for sensing an operating parameter of the delivery unit (eg, battery strength, whether the delivery unit is presently in a "delivery"
mode or in an "oft" mode, therapeutic agent dosing history, amount of therapeutic agent remaining in the delivery unit, device malfunction, etc) 2o and transmitting the system parameter condition back to the control unit, through the return telemetry link, where it is appropriately received and displayed for the benefit of the operator. Alternatively, the delivery unit may have a patient activated switch for indicating an emergency condition which is transmitted to the control unit to set off an alarm, In addition to the patient as activated alarm, the delivery unit may contain rnearls for sensing geographical location (eg, through antenna or satellite based global positioning systems) and transmitting said location to fhe control unit.
WO 96!13302 ~ ~ fi ~ .i ~ % PCTlUS95113218 One advantage of separating the control unit and the delivery unit by the telemetry link lies in the opportunity to add features to the delivery unit in the space that is otherwise unavailable if the control and delivery unit are physically combined.
s BRIEF DESCRIPTION OF THE DRAWINGS
Reference is made, in the following detailed description, to Figs. 1 to 4 in which like parts are designated by like reference numerals, io and in which;
Fig. 1 is a schematic of an electrotransport delivery system having a radiated energy telemetry link between a control unit and a delivery unit.
is Fig. 2 is a diagram of an electrotransport delivery system having a radiated energy telemetry link illustrating the remotely located control unit transmitting a control signal to the electrotransport delivery unit.
Fig. 3 is a diagram of an electrotransport delivery system illustrating a zo remotely located control unit receiving a response signal from an electrotransport delivery unit.
Fig. 4 is a detailed block diagram of one embodiment of a electrotransport delivery system having a telemetry link between a control zs unit and a delivery unit.
MODES FOR CARRYING OUT THE INVENTION
With reference to Fig. 1 there is shown a schematic diagram of an so electrotransport system having a remote telemetry link for programming and receiving system information in accordance with this invention and generally wo 9somoz ~ ~ ~~ ~ ~ :~ ~ Pc~r~us~snaz~s indicated by the numeral 20. The system 20 includes a control unit indicated by the numeral 22 and a delivery unit indicated by the numeral 24. The control unit 22 and delivery unit 24 are spaced apart and electrically isolated from each other. The delivery unit 24 includes a power source 26. The s source 26 provides a source connection 28 and a return connection 30 for supplying an efectrotransport current, I. Switch means 32 connects in series with the power source 26 and a first electrotransport electrode 34. The first electrode 34 is configured to make confact with the skin 40 of a patient's body. The first electrode 34 contains a therapeutic agent 36, such as a ~o drug, which is responsive to the electrotransport current I, for delivery through the skin 40. A return electrode 38 provides the return path for the current I from thi? skin 40. The return electrode 38 connects to the return connection 30 of the power source 26.
~s The power source 26, switch means 32, electrode 34, skin 40 and return electrode 38 thus form a complete circuit for the eiectrotransport current, I
The delivory unit 24 includes a receiver 42. The receiver 42 is zn configured to reeeive and respond to a radiated energy signal 54 by outputting a control signal 44 upon receiving the signal 54. The control signal 44 connects to switch means 32. The switch means 32 is configured to respond to the control signal 44 by closing a switch 41 between the source 26 and the delivery electrode 34 thereby enabling electrotransport z~ current I to flow.
The contiol unit 22 includes a transmitter 50 responsive to the input signal 48. Transmitter 50 produces a radiated signal 54 upon receiving an input signal 48. Closure of an input switch 46 connects input signal 48 with so a second input 49 of control unit 22.
67696-229 , In one simple embodiment in accordance with this invention, the transmitter 50 of the control unit 22 produces the signal 54 as long as the switch 46 is closed and the input signal 48 is present. The receiver 42 outputs a control signal 44 as long as the signal 54 is being received, and s the switch 47 remains closed, providing current I to deliver the therapeutic agent 36 through the patient's skin 40.
In the embodiment of Fig. 1, the agent 36 is contained in the electrode 34 connected as an anode. Other embodiments may be used, in ,o which the agent to be delivered is contained in the cathodic electrode 38, or wherein agents are contained in both electrodes. The power source 26 is shown as a battery with only a single direct current (DC) voltage supply.
It is contemplated that the power source 26 could be a combination of DC and/or alternating current (AC) sources providing complex DC and/or AC
,s waveforms or a combination of DC levels and/or ramps as desired:
The control of electrotransport current I, is shown as a simple switch 47 of switch means 32 whereby the "control" of current, l, is simply one of on or off. Besides a simple on/off type of current control, it is contemplated zo that more complex control over the magnitude, polarity, waveform shape, pulsing frequency, duty cycle, etc. of the current I and dosing time may be obtained by using more complex electrotransport circuits as described below.
The switch means 32 can include a magnetically actuated reed switch is in place of or in addition to the switch 47 for_ controlling the current, I. Reed switches have been used in implanted devices such as cardiac pacemakers.
See, for example, Alferness et al, US Patent 4,066,086;
Berntson US Patent 4,676,248; Hartlaub et al, US Patent 4,401,120, and Bowers US Patent 3,311,111. A magnetically activated reed switch provides so an added means of redundancy for preventing unwanted radiated signals from causing ~''' _nlf._.~~
W096113302 ~ ~ ~.~ PCTI1TS95f1321$
inadvertent drug delivery by ensuring that the current, l, is not delivered unless the reed switch is closed. This can be accomplished by passing a sufficiently strong magnet leg, in the form of a magnetic wand] over the delivery unit 24 during transmission of signal 54. Once the signal 54 is s received by the delivery unit 24, the magnetic wand may be removed from its position over the unit 24 to open the reed switch to ensure that extraneous radiafed energy signals have no effect on the subsequent operation of unit 24.
io Similarly, with reference to Fig. 4, a magnetically actuated reed switch (not shown] can be connected in series with the connection between the OUT signal of DRtI 168 and the IRQ1' signal of DMGU 160. In this case, programming signals transmitted by the transmitter GTS 154 have no effect on the programmiri~ of drug delivery by the delivery unit 130, unless the is reed switch is closed. Closure of the reed switch is accomplished by passing a magnet leg, a magnefic wand) of sufficient strength in close proximity with the reed switch. Rgain, this provides an additional margin of safety and immunity to extraneous radiated signals. -zo The delivery unit 24 may be mounted on the patients' body by conventional means, such as s#raps (not shown] aftached to the delivery unit 24 and encircling the trunk or limb of the patient. Alternatively, the delivery unit 24 may be attached to the patients' skin by means of adhesive film around the periphery of the electrodes 34, 38. An "in-line" adhesive on the zs skin-contacting surfaces of electrodes 34, 38, which adhesive is permeable to the therapeutic agent 36 and other ions under the influence of the applied electric potential, may also be used to attach the delivery unit 24 to the patients' skin 40.
,r-.j ~. ~:,. ..., WO 96113302 ~" ' ~ ~ '~ '~ ~ PCT/US95I13218 The physical separation and electric isolation between the control unit 22 and fhe delivery unit 24 provides much greater freedom in terms of separately mounting the control 22 and delivery unit 24. The delivery unit 24 may be mounted anywhere on the patient's back, neck, shoulders, head, s buttocks, back of legs, under arm or other areas not easily observed or reached. The control 22 unit may be kept in any convenient location, such as strapped to the patient's wrist, in a pocket or pocketbook or elsewhere.
io Radiated energy signals 54 of different types are contemplated for use in accordance with this invention. One preferred embodiment of this invention uses radio frequency (RF) signals 54 for the transmitter 50 and receiver 42 of the telemetry fink. Radio frequency signals may be modulated by amplitude modulation (AM), frequency modulation (FM), frequency shift is keying (FSK), phase shift keying (PSK) and the like. There is generally a trade off between modulation complexity and transmitter power consumption.
AM is generally simpler but less efFcient in terms of transmission range for a given power supply drain and signal to noise ratio (SNR). FM, FSK and PSK
are progressively more efficient for power supply drain and SNR
za considerations but require progressively more complex modulation circuits.
One useful reference regarding RF modulation methods is fhe Electronics Engineers Handbook, 3rd edition, Fink et al, McGraw Hill, New York, NY, 1989, chapter 14.
zs While the present invention is not limited to any particular frequency range, the frequency range of operation for the RF transmission is typically between about 1 MHz and 1000 MHz. One preferred frequency is about 310 MHz, corresponding to the industrial frequency band.
N ' ~ f~j .; J
WO96l13302 ~ ~ PCT'ltlS9i/13218 While the present invention is not limited to any particular power level for transmitter 50, a power level of up to 100 mW in accordance with I=CC regulations is contemplated for patient operated control units (ie, in those cases where the person operating the control unit is also s wearing the delivery unit). In one embodiment, a range of operation of up to about one meter was obtained with only 0.1 mW of transmitter power at a frequency of 310 MHz using coiled antennas (not shown) of about 2.5 cm diameter for the receiver 42 and about 5 cm diameter for the transmitter 50. A range of up to about 8 meters was obtained with a ~o transmitter poweuof about 100 mW and similar antenna sizes.
in other eriibodiments of the present invention, it is cantemplafed that the range of operation beturreen the control unit 22 and the delivery unit 24 may be extended up to hundreds or even thousands of kilometers, by ,s selecting appropriate communication channels having relay links such as cellular phone networks, satellite communication links and the like.
Limiting transmitter power for the control unit 22 is not of as great concern, as the size of the control unit 22 is under fewer constraints than the so size of the delivery unit 24 and therefore the control unit 22 can be made larger to accommodate larger sized batteries (in the case of a hand-held, patient-activated control unit 22), ar be in the form of a table or desk sized control unit 22 which is plugged into a standard electrical outlet (in the case of a control unit 22 for controlling delivery units 24 wom by zs patients in a hospital ward), or be in the form of a control unit utilizing large tower-sized transmitting antenna (in the case of a control unit 22 for controlling th~=~ delivery units 24 of patients located in a particular geographic region, eg, a cityor county).
r~ ~ .~., G. I ~~ ~ ..~ ..~ i' WO 96!13302 PCTIUS95/13218 Another radiated energy signal 54 contemplated for use in accordance with this invention is electromagnetic induction (EMI) using coupled coils (not shown). The coupling of radiated signals between coupled coils is determined by the mutual inductance of the coils. Calculations for the s mutual inductance of coils are shown in the US Bureau of Standards Circular C74, US Government Printing Office, and Bulletin of the Bureau of Standards Val. 8 printed 1912 and Vol. 18 printed 1918. Suitable coupled coils may be selected far transmission of radiated energy signals over a desired distance.
~o Yet another radiated energy signal contemplated for use in accordance with this invention, are ultrasonic waves transmitted and received by means of ultrasonic transducers. Infrared (IR) emitters and detectors may be used for radiated energy signal transmission in accordance ~s with this invention.
With reference to Figs. 2, 3 and 4, there is shown a particular embodiment of an electrotransport system having a telemetry link between control and delivery units in accordance with this invention and indicated zo generally by the numeral 100. In Fig. 2, a control unit 102 includes control buttons 104, 106, 108, and 110, an indicator LED 112 and an audio annunciator 114, such as a speaker or piezoelectric transducer. The control unit 102 transmits a radiated energy signal 120, by actuation of buttons 104-110 as explained below, to a delivery unit 130. Delivery unit 130 is 2s positioned on the skin of a patient (not shown) by means well known in the art, such that electrotransport electrodes 132 and 134 are in contact with the patient's skin The unit 130 provides electrotransport current, under control of the signal 120 as described below, to the electrodes 132 and 134 such that a therapeutic agent 136 contained in electrotransport electrode 132 is so delivered as desired.
ADO 9b113302 , ~ ~ ~:, ~ PCTIUS95f 13218 #~ ~ ~ ~ ~' ,.? t With reference to Fig. 3, there is depicted the delivery unit 130 transmitting a radiated response signal 122 to the control unit 102. The delivery unit 13D transmi#s the response signal 122 fo the control unit 102 under predetermined conditions described below. The control unit 102 is s configured to respond to the response signal 122 by displaying a predetermined sequence of lights on the LED 112. The control unit 102 may also be configured to respond to the response signal 122 by emitting a sequence of sounds or tones from the audio annunciator 114. In an alternate embodiment of the control unit 102, the audio annunciator 114 may be io replaced by an LCD or LED display unit configured to display alphanumeric information resulting from the response signal 122.
With reference to Fig. 4, there is shown a schematic diagram of the electrotransport sysfem 100 of Fig. 2 and 3, illustrating a preferred ~5 embodiment of a remote telemetry fink between control unit 102 and delivery unit 130 for i:rogramming and control in accordance with this invention.
The control unit 102 includes a micro-controller unit (MCU) 150, a first remote-control transmitterlreceiver unit (CTU) 152, a control transmitter stage so (CTS) 154, a second remote-control receiver unit (CRU) 156, and a control receiver stage (CRS) 158. Indicator devices, such as audio annunciator 114 and LED 112, are also included fot communicating system and/or patient state: information to an operator. Power and ground connections to the individu~i components are made in a suitable conventional manner.
One implementation of the present invention uses a MC68HC7051C1 ('705) 8-bit micro-controller, available from Motorola Semiconductor Products, Inc., Phoenix, Arizona for the MCU 150. The '705 includes an on-chip memory-with 504 bytes of erasable, programmable ROM (EPROM), ao 32 bytes of User RAM and a 64-bit EPROM. The'~05 may be programmed to provide desired output signals on the bidirectional, software programmable ~!'lU.'r WO 96f13302 PCTIUS95113218 pins, PA6, PA3, and PA4, and to respond to inputs on the bidirectional pins IRQ\, PAO, PA1, PA2, PAS, PA7, PBO. Switches 104, 106, 108, 110 provide inputs to pins IRO\, PAO, PA1 and PA2, respectively.
s The pin PA3 is configured as an output and connects to the audio annunciator 114. The pin PA4 is conftgured as an output and connects to the LED 112_ The annunciator 114 and LED 112 are provided with suitable connections to the system ground of the control unit 102.
~a In one implementation, the MCU 150 is programmed to treat the IRQ1 input as an interrupt. A logic low level on the IRO\ input puts the MCU 150 in a state waiting for succeeding switch actuation on inputs 106, 108, 110 to perform desired operations as described below.
~5 The CTU 152 and GRU 156 are each TMS3637 ('3637) programmable remote-control transmitterlreceiver units available from Texas Instruments, Dallas TX. The '3637 is a remote-control transmitter/receiver. The '3637 contains 31 bits of EPROM. These 31 bits can be programmed into two groups: 22 bits to store a unique code, and 20 9 bits to configure the '3637 as either a transmitter or a receiver. The total number of combinations for the stored code is 222 or 4,194,304 combinations. The CTU 152 and CRU 156 are programmed with different codes so that transmission of signals by CTS 154 and receipt of signals by CRS 158 may be securely differentiated as described in more detail below.
When the "3637 operates as a receiver, it can identify the 22-bit code for which it is programmed and consequently generates one pulse or toggles the state of an output pin, OUT. When the '3637 operates as a transmitter, it emits 22 bits of code when triggered by an external command or so continuously as tang as power is applied. The programming method is R d ~~
Wo96113302 ~' ~ ) ~) N° ...~ ~ PCTlUS95J1321$
described in the TMS3637 data sheet available from the Texas Instruments, Dallas, TX herein incorporated by reference.
The CTU 152 is programmed as a continuous mode transmitter, so s that a low level on the TIME input of CTU 152 causes a continuous transmission of the 22-bit control code on the OUT pin of CTU 152 as long as the CTU i 52 TIME input is low. Output PA6 of MCU 150 connects to the TIME input of CTU 152.
~o The I~IiCU 150 is programmed to cause the output PA6 to remain low for a period dependent on which of the switches 106, 108, 110 were selected after switch 104. For example, the PA6 output may be programmed to provide a low level for 5, 10 or 15 minutes, depending on the selection of switch 106, 108 or 110 respectively. The MCU 150 may also be 75 programmed toindicate which period was selected by flashing the LED 112 or beeping the annunciator 114 for a predetermined number of times, eg, 1, 2 or 3 for the 5, 10, or 15 minute period selected. This provides the operator with cohfirmation that the desired dosage time was selected.
zo The CTU 152 is programmed to output the transmitted code continuously on the OUT output of CTU 152. ThE CTLI 152 is driven at a suitable clock rate, for example, 5.7 kHz by a clock source (not shown).
The OUT signal drives the input of the CTS 154 transmitter. The CTS 154 is configured as a conventional low power AM transmitter consistent with zs FCC requlremehts to limit output power to 100 mW or less. The CT5 154 may be implemented with conventional printed circuit board and transistor technology as is uvell known in the art. A 2.5 cm microstrip antenna is a suitable transmitting antenna at a carrier frequency of,310 MHz.
A conventional transistor LC tuned collector circuit coupled to the microstrip so antenna {not shown) provides a suitable transmitter for amplitude modulation {AM) transmission in the CTS 154.
L ~ ~i''iJ.i.Jfl A base tuned transistor circuit (not shown) would also be a suitable transmitter stage for the CTS 154. For example, a Surtace Acoustic Wave resonator such as CW SAW oscillator available from R.F. Monolithics, Inc, Dallas, TX, may be used in the base circuit of a transmitter stage 154 and s modulated b', the OUT signal from CTU 152.
It is contemplated that frequency modulation (FM) would provide a lower power transmitting/receiving system for the electrotransport telemetry system 100 at this invention. It is further contemplated that Frequency Shift ~o Keying (FSKi. or Phase Shift Keying (PSK) would provide a still lower power transmittingireceiving system for the electrotransport telemetry system of this invention, at tfae expense of more complex modulating and demodulating circuitry.
~s The delivery unit 130 includes a delivery micro-controller (DMCU) 160, a delivery receiver stage (DRS} 164, a delivery transmitter stage (DTS) 166, a delivery remote-control receiver unit (DRU} 168, a delivery remote-control transmitter unit (DTU) 170, a current-control-unit (CCU) 172, a current-sense-unit (CSU), a series sense resistor, R, and electrotransport zo electrodes 13t and 134. The electrode 132 contains a suitable therapeutic drug or other agent 136 for delivery by electrotransport.
The DMCU 160 may be anofher MC68HC705K1 8-bit micro-controller and the DTU 'i l 0 and DRU 168 may be another pair of TMS3647 devices zs configured as a remote-control transmitter and receiver, respectively.
A low voltage power source, such as one or more 3-volt lithium coin cell batteries (~sAn02/Li) or the like may be used as the power supply for the delivery unit 130. Lithium coin cells are well known in the art and are so available from several commercial sources, such as Panasonic, Matsushita, WO96l13302 ;'1 "" '~ j PCl'lUS95II3218 '.'~ ~U ~i .J
and Duracell. Power and ground connections for the control unit 130 are made in a conventional manner.
The DRS 164 receives the signal 120 from the CTS 154 transmitter.
s The DRS 16~t is configured as an AM receiver to amplify, detect and demodulate the signal 120 and convert it to an output signal connected to the remote-control receiver unit DRU 168. The output signal from the DRS 164 is connected to the TIME input of the DRU 168. DRU 168 is programmed as a Valid Transmission Receiver (VTR) as described in the ,o TMS3637 data street, op cit. The VTR programmed DRU 168 is responsive to the same code transmitted by the CTS 154. The VTR response is programmed to produce a high level signal on the OUT pin of the DRU 168 as long as the transmitted signal 120 continues to provide the transmitted 22-bit code. The OUT pin of DRU 168 is connected to the IRQ\' pin of the ,s DMCU 160. The IRQ\' pin of DPJICU 160 is programmed to generate a high !eve! output on the PA7' pin as song as the OUT logic level fram DRU 168 is high. The high level on PA1' corresponds to a demand for delivery of electrotransport current, I.
as The output PA1' of DMCU 160 connects to an input 176 of the electric current supply unit (ECU) 172. The ECU 172 may be configured as a constant (or non-constant) current source responsive to a high level on the input 176. The ECU 172 includes a source current output connection 178 and source currenf return connection 180. The ECU 172 is adapted to 25 provide sufficient current. 1, to drive the therapeutic agent 136 contained in electrode 132 into the patients' skin. The return electrode 134 is connected to one side of the sense resistor R. The other side of the sense resistor R
provides a return path for the current I to the return connection 180 of ECU 172.
The current sense unit (CSU) 174 is connected across the sense resistor R by sense pins 182 and 184. The CSU 174 is configured to provide a hioh level signal on output 186 if the current I through the resistor R produces a voltage less than a predetermined amount for the dose rate s desired. This may 'occur if the resistance of the patients' skin is too high such that the CSU 174 comes out of compliance or the electrodes become dislodged from the skin. In either case the ECU. 172 will not be able to supply the necessary current and the desired dose will not be delivered.
The output 186 is connected to an input PA2' of DMCU 160. The PA2' input ,o is programmed as an active high input. In the event that CSU 174 senses the current, I ,is not in compliance, the high level output signal 186 is received by the DMCU 160 input PA2'.
A mope detailed description of a suitable electrical current source ~ s ECU 172 and current sense unit CSU 174 may be found in European Patent EP 0781152, published April 4, 1996.
zo The DMCU 160 is programmed to provide a low level on an output PA6' when the input signal PA2' from output signal 186 is a high level and the PA1' signal is high. This indicates that the desired electrotransport current, I, is not being delivered as desired.
zs Output PA6' connects to the TIME input of the DTU 170.
The DTU 1 r a is configured as a remote-control transmitter as described in the TMS363 i data sheet op cit. The DTU 170 is programmed to transmit a second 22-bit coded signal on the DTU 170 OUT pin when the Time input of DTU 170 is low. The second coded signal on OUT pin of .DTU 170 is so connected t~ an input of DTS 166. DTS 166 may also be configured as an AM transmitT~~~ stage converting the OUT signal, 170 to an AM modulated RF
{ .: -4 ,,-..
WO96l1330Z 1-' i '~ ~-J ..~ PCT/US9il13218 signal 122 at a suitable carrier frequency of about 310 MHz. DTS 166 modulates the second 22-bit coded OUT signal 170 and Transmits the second coded RF signal 122.
s The second coded RF signal 122 is received by CRS 158 of the control unit 1 U2. CRS 158 is configured as an AM receiver to detect, demodulate and amplify the received RF signal 122 and present the demodulates. output to the TIME input of CRU 15&.
to The CRU 156 is configured as a receiver, as described in the TMS3637 data sheet, responsive to The same code programmed in the DTU 170. Upon receiving the demodulated second coded signal 122 from CRS 158, CR'J 156 provides an output on the OUT pin of CRU 156.
The OUT pirt of CRU 156 connects to another programmed input pin of the 15 MCU 150, fer example, PA7. The input PA7 of the MCU 150 is programmed to be an input responsive to the OUT signal of CRU 156.
The MCU 150 is programmed fo provide an indication to the operator that the current, I, is-not in compliance by toggling the pins PA3 and PA4 (hereby flashing the !_FD 112 andlor sounding the annunciator 114 with a zo predetermined pattern, The operator may then act appropriately by checking the connection of the electrodes 132 and 134, or locating them to an area which makes better contact with the patient's skin.
From the foregoing description of the sense resistor R, ECU 172, zs CSU 174 and DhiiCU 160, those skilled in the art wilt readily appreciate that any number of patient body parameter conditions andlor delivery unit 130 conditions can be checked and transmitted to the remote control unit by means of D T S 166 and CRS 158. For example, means for sensing a body parameter such as a thermometer for sensing body temperature, a piezo a~ electric device for sensing body or muscle movement, a.blood glucose sensing element; and/or a blood gas sensing element may be substituted for W0 96113302 G i ~~ ~ .! .l ~ PCTlUS95113218 the sense resistor R and associated circuitry in order to provide other types of sense signals relating to the particular parameter being sensed. In addition, me<jns for sensing a parameter of the delivery unit 130 may also be sensed and transmitted in a similar fashion. For example, a counter which s counts the number of doses delivered from the delivery unit 130 may transmit this dosing information. Other system parameters such as battery strength, amount of therapeutic agent remaining to be delivered, whether the delivery unit is currently operating in an "on" or an "off' mode, and whether or not a system malfunction has occurred could also be sensed by an to appropriate sensing means and transmitted via the transmitting and receiving means.
In other embodiments of the electrotransport telemetry system in accordance with this invention, MCU 150 may be programmed with a ~5 plurality of control programs, as is well known in the art. The plurality of programs, may include providing multiple patterns of delivery. For example, one program may provide an output signal on the PA6 output to the TIME
input of the CTU 152 having a sequence of predetermined periods such as 10 minutes of delivery followed by 50 minutes of non-delivery. This pattern zo may be repeated by a desired number of repetitions, as programmed.
Any number of delivery profiles may be programmed into MCU 150.
Alternatively, a program may choose different delivery and non delivery intervals and repetition sequences to be selected by differing actuation of the input switches 104 - 110.
The MCU 150 may also be programmed to react in predetermined fashion to signals received from the CRS 158 and CRU 156. For example, one program may provide alternative display patterns on the annunciafor 114 ar LED 112 in response to signals transmitted by DTS 166 and DTU 170, by ao flashing or sounding at a rapid rate to indicate an abnormal condition (eg, too low cr too high a drug delivery rate) regarding the drug delivery.
R'O 96113302 ~ ~ '~ ~ J .: ~ PCT/1IS95113218 It is contemplated that the embodiments of the invention may be combined in various combinations to provide, for example, a dosage regimen having a predetermined pattern customized by the physician fior a particular patient, that is programmed into the control unit 102.
s The inputs IRQ\, PAO, PA1, PA2, of the control unit 102, connected to control switches 104-110, could be programmed to provide different optional dosage patterns on patient demand. The delivery unit 130 could be configured with different sensor osrcuitry having signals responsive to other ~o conditions, such as the oxygen or carbon dioxide content of the patient's tissue, hear rate, skin impedance, skin temperature and the like. These signals may be fed back to the control unit 102 by means of the telemetry link of this invention providing a compact delivery unit in a system having improved performance. Other embodiments of this invention incorporating 1s numerical di~,plays, such as multiplexed LCD displays connected to the MCU 150, are contemplated as within the scope afthe claims.
While the foregoing detailed description has described an embodiment of the electrotransport system having a telemetry ii~k communicating zo between contras and delivery units in accordance with this invention, it is to be understecd that the above description is illustrative only and not limiting of the disclosed invention. It will be appreciated that it would be possible to modify the number and type of control circuits and delivery circuits, the materials and methods of construction and the logic forms and zs interconnections or to include or exclude various elements within the scope and spirit of the invention. Thus the invention is to be limited only by the claims as set forth below.
More recently, small self contained electrotranspor# delivery devices adapted to be wom on the skin, sometimes unobtrusively under clothing, for extended periods of time have been proposed. The electrical components in io such miniaturized electratransport drug delivery devices are also preferably miniaturized, and may be either integrated circuits lie, microchips) or small printed circuits. Electronic components, such as batteries, resistors, pulse generators, capacitors, etc., are electrically connected to form an electronic circuit that controls the amplitude, polarity, timing, waveform shape, etc. of 3s the electric current supplied by the power source. Such small self contained electrotransport delivery devices are disclosed far example in Topper US Patent 5,224,921; Siba(is et al US Patent 5,224,928 and tiaynes et al US Patent 5,246,418.
z~ Wrth regard to providing electrical current to electrotransport electrodes, Henley U.S. Patent 5,1fi0,316 discloses a generator driving a primary isolated current loop. The current loop feeds current to individual channels in a wide area, multi-channel electrode via a plurality of individual secondary current Poops. The isolated primary current loop is disposed in zs adjacent, but insulated alignment with the individual secondary current loops far close inductive coupling. There is no power source for the electrotransport currents except the coupled current from the isolated primary current loop. The controls and switches for the isolated primary current loop are contained iri a control box connected to the primary current loop. The so current loops in Henley must be very closely coupled to have efficient transfer of current. If the current loop were physically separated by a WO 96!13302 ~ ~ ~ PCT/ITS95l13218 significant distance, say several feet, from the individual current loops, the control of the electrotransport current, and hence the rate of electrotransport drug delivery, would vary considerably.
s One concern, particularly with small self-contained electrotransport delivery devices that are adapted to be wom on the body andlor under clothing, is the diffiiculty and inconvenience of using controls or reading indicators on the device. This is also a concern (ie, from the standpoint of viewing the electrotransport delivery device or to manipulate controls ~o thereon) when the electrotransport device is worn on an inconvenient area of the body, such as the back, the upper outer arm, and the like. Also, whereas it is convenient to have very small delivery units that are unobtrusive, it is a disadvantage if the delivery unit has controls that are too small to be effectively manipulated, or indicators (eg, LED's) that are too is small to be clearly seen, by a substantial portion of the population (eg, the elderly).
It may be desired, for example, to have a start button on the electrotransport device that initiates drug delivery on demand of the patient.
zo Wi#h a small, self-contained unit, the placement of the unit on the patient's body is usually limited to a body location that the patient can both see and reach. The limited location option may interfere with the efficacy of the therapy. Thus, in certain situations it would be an advantage to separate the controls for controlling the operation of the electrotransport delivery device zs from the device itself.
It may also be desired to obtain some delivery system information for the benefit of the user or a medical attendant. Examples of such delivery system information include the dosing history, amount of drug remaining in ao the system to be delivered, battery life, whether the system is presently in a "delivery" mode or an "off' mode, etc. There have been proposals to WO96113302 ~w~ ~"~ A~ ~ '°~, ~ PCTIUS9S113218 incorporate patient monitoring features into electrotransport drug delivery devices. One example is blood glucose monitoring for an electrotransport insulin delivery device. Thus, if the sensed glucose levels become too high, the glucose level indicator would instruct the patient to activate the device to deliver insulin. Other types of patient information besides blood glucose levels could also be sensed and displayed on an electrotransport device indicator far the benefit of the patient ar a medical technician. For example, application of therapeutic drugs, whether by electrotransport or more traditional leg, oral) dosing, can sometimes cause unwanted reactions in ~a certain patients. These reactions can take many farms, including respiratory depression, change in heart rate, change in body temperature, sweating, shaking and the like. It would be advantageous to provide this system and/or patient information to a remote indicator so that the information may be read at a remote location leg, at a central nurse's station in a ~s hospital ward). This would enable a nurse or attendant to take action without having to check the delivery device worn by the patient, remove the patient's clothing ar otherwise disturb the patient:
It would clearly be desirable to have electrotransport delivery systems za available in a configuration with the controls and indicators mounted on a control unit that is remote from the delivery unit. The present invention provides the needed improvement without diminishing the intended therapeutic efficacy of the device or the therapeutic substance to be administered.
There is a need for an electrotransport device for administering a drug through a body surface leg, skin), having complete freedom of placement of 3o delivery electrodes, without compromising the ability of the patient ar a medical technician to control the operation of the device.
RTO 96!13302 ~. i ~% ~ ..i' .j ~' PCTlUS95113218 There is also a need for an electrotransport device having improved access to controls and status indicators independent of the location of the delivery device on a patient's body.
s There is a furkher need far a small electrotransport delivery device adapted to be worn by the patient unobtrusively (eg, under clothing ) for which the control and display features are not limited by the size of the device.
,o The present invention is directed to an electrotransport system for delivering a therapeutic agent through the skin of a patient, that satisfies the needs described above. The electrotransport system is comprised of a control unit and a delivery unit, which two units are remote from one another and communicate with one another using telemetry. The delivery unit is ~s adapted for mounting on the body surface (eg, skin) of a patient. The delivery unit includes a pair of electrodes, at least one of which is a "donor"
electrode containing the therapeutic agent (eg, a drug) to be delivered through the body surface (eg, skin). The delivery unit also includes a source of electrical power (eg, one or more batteries) which is electrically zo connectable to the electrodes in order to apply an electrotransport current through the electrodes and the patient. The system is characterized by a telemetry communication link between the delivery and control units whereby the units communicate by means of a radiated energy signal transmitter means and a radiated energy signal receiver means.
zs In a preferred embodiment, the control unit communicates with the delivery unit in order to control the electrotransport current applied to the patient, and thereby control the delivery of the therapeutic agent to the patient. In a more preferred embodiment, the delivery unit includes a so receiver means adapted for receiving a radiated energy signal which is transmitted by the control unit and providing a control signal responsive WO9b1t3302 "~ ~ »~'~ ~ ~.y~ PCT/OB95Ii32t8 thereto. The delivery unit also includes a current control means adapted to control {eg, control the initiation, interruption, magnifude, polarity, waveform shape, pulsing frequency, and/or duty cycle) the electrotransport current applied. The current control means is responsive to the control signal from s the receiver means. The control unit, which is remote from the delivery unit wom by the patient, preferably includes a transmitter means. The transmitter means is responsive to an input signal, for example, a preprogrammed and/or a manually selected input signal chosen by the operator leg, the patient or a medical technician). Upon receiving the input signal, the ,o transmitter means Transmits a radiated energy signaC {eg, an infrared signal, a radio frequency signal, or an ultrasonic signal) to the receiver means in the delivery unit, whereby the electrotransport current applied by the delivery unit is controlled by the input signal to the remote control unit.
~s The distance separating The control unit from the delivery unit is limited only by the strength of the transmitted radiated energy signal Tram the transmitter means, the signal-to-noise ratio of the receiver means and the radiated energy modulation scheme selected for the particular implementation. The distance can range from quite small 20 leg, several centimeters) to very large leg, hundreds of kilometers).
The control unit may be a small, lightweight unit leg, a wand or hand held unit) and optionally may be mounted on an easily accessible part leg, the wrist or lower arm) of the patient's body, Alternatively, the control zs unit may be a larger unit leg, desk size) with a more powerful transmitter adapted to operate within, eg, several hundred meters of the delivery unit.
In such caws, the control unit may be operated from the patient's bedside ar from a centralizetf nursing station in a hospital ward WO 96113302 ~ ~ ~~~ ~~ ..? s_t ! PCT/US95li32i8 The control unit may optionally include a plurality of manually operated switches adapted to provide a plurality of signal inputs to the control unit for transmitting a plurality of signals to the delivery unit.
The electrotransport control unit may also optionally include a microprocessor having a plurality of inputs connected suitably to the plurality of switches. The microprocessor has an output connected to the transmitter for controlling the radiated energy signal to be transmitted. The microprocessor may have a plurality of stored programs for providing a io corresponding plurality of control signals. The operator selects one of the stored programs, eg, by selecting one of a plurality of manually operated switches in order to cause the delivery unit to deliver an electrotransport current of predetermined amplitude, timing, etc, which corresponds to the operator's selection.
The telemetry link may be provided by one of a number of radiated energy transmitting and receiving means. In a preferred embodiment, the radiated energy is radio frequency (RF) radiated energy over a range of frequencies of between about 1 MHz to about 1000 MHz. The radio zo frequency energy may be modulated by amplitude modulation, frequency modulation, frequency shift keying, or phase shift keying. Alternatively, the radiated energy may be in the form of ultrasonic radiant energy, optical radiant energy or by the radiant energy of electromagnetic induction.
z5 The electrotransport telemetry may include a coding and decoding means for coding the transmitted signals in a predetermined security code.
Coding the transmifted signal provides additional security against falsely initiating agent delivery due to unwanted signals such as extrinsic radiant energy interference.
wo vsras3o2 ~. pc~rrUSVSnsms 1 d~"
~1~~CJ~
The electrotransport telemetry system of this invention may include a sensor means mounted in the delivery unit for sensing a predetermined patient body parameter condition, such as breathing rate, blood glucose concentration, skin resistance, body motion, muscle movement s (eg, contraction); tissue oxygen content, tissue carbon dioxide content, body temperature, heart rate, sweat response or the like. The sensor means may provide a sense signal to a return radiated energy transmitter means for transmitting a return radiated energy signal to the control unit. The control unit may have a corresponding receiver for receiving the return radiated ~o energy signal from the delivery unit. The control unit may include an indicator for displaying the sensed parameter condition by any type of conventional display means including LED, LCD display, audio annunciator ar the like and in the case of a larger size control unit the indicator for displaying the sensed parameter may be a cathode ray tube, or other type of ,s video screen, a printer or the like. Alternatively, the delivery unit may have a sensor for sensing an operating parameter of the delivery unit (eg, battery strength, whether the delivery unit is presently in a "delivery"
mode or in an "oft" mode, therapeutic agent dosing history, amount of therapeutic agent remaining in the delivery unit, device malfunction, etc) 2o and transmitting the system parameter condition back to the control unit, through the return telemetry link, where it is appropriately received and displayed for the benefit of the operator. Alternatively, the delivery unit may have a patient activated switch for indicating an emergency condition which is transmitted to the control unit to set off an alarm, In addition to the patient as activated alarm, the delivery unit may contain rnearls for sensing geographical location (eg, through antenna or satellite based global positioning systems) and transmitting said location to fhe control unit.
WO 96!13302 ~ ~ fi ~ .i ~ % PCTlUS95113218 One advantage of separating the control unit and the delivery unit by the telemetry link lies in the opportunity to add features to the delivery unit in the space that is otherwise unavailable if the control and delivery unit are physically combined.
s BRIEF DESCRIPTION OF THE DRAWINGS
Reference is made, in the following detailed description, to Figs. 1 to 4 in which like parts are designated by like reference numerals, io and in which;
Fig. 1 is a schematic of an electrotransport delivery system having a radiated energy telemetry link between a control unit and a delivery unit.
is Fig. 2 is a diagram of an electrotransport delivery system having a radiated energy telemetry link illustrating the remotely located control unit transmitting a control signal to the electrotransport delivery unit.
Fig. 3 is a diagram of an electrotransport delivery system illustrating a zo remotely located control unit receiving a response signal from an electrotransport delivery unit.
Fig. 4 is a detailed block diagram of one embodiment of a electrotransport delivery system having a telemetry link between a control zs unit and a delivery unit.
MODES FOR CARRYING OUT THE INVENTION
With reference to Fig. 1 there is shown a schematic diagram of an so electrotransport system having a remote telemetry link for programming and receiving system information in accordance with this invention and generally wo 9somoz ~ ~ ~~ ~ ~ :~ ~ Pc~r~us~snaz~s indicated by the numeral 20. The system 20 includes a control unit indicated by the numeral 22 and a delivery unit indicated by the numeral 24. The control unit 22 and delivery unit 24 are spaced apart and electrically isolated from each other. The delivery unit 24 includes a power source 26. The s source 26 provides a source connection 28 and a return connection 30 for supplying an efectrotransport current, I. Switch means 32 connects in series with the power source 26 and a first electrotransport electrode 34. The first electrode 34 is configured to make confact with the skin 40 of a patient's body. The first electrode 34 contains a therapeutic agent 36, such as a ~o drug, which is responsive to the electrotransport current I, for delivery through the skin 40. A return electrode 38 provides the return path for the current I from thi? skin 40. The return electrode 38 connects to the return connection 30 of the power source 26.
~s The power source 26, switch means 32, electrode 34, skin 40 and return electrode 38 thus form a complete circuit for the eiectrotransport current, I
The delivory unit 24 includes a receiver 42. The receiver 42 is zn configured to reeeive and respond to a radiated energy signal 54 by outputting a control signal 44 upon receiving the signal 54. The control signal 44 connects to switch means 32. The switch means 32 is configured to respond to the control signal 44 by closing a switch 41 between the source 26 and the delivery electrode 34 thereby enabling electrotransport z~ current I to flow.
The contiol unit 22 includes a transmitter 50 responsive to the input signal 48. Transmitter 50 produces a radiated signal 54 upon receiving an input signal 48. Closure of an input switch 46 connects input signal 48 with so a second input 49 of control unit 22.
67696-229 , In one simple embodiment in accordance with this invention, the transmitter 50 of the control unit 22 produces the signal 54 as long as the switch 46 is closed and the input signal 48 is present. The receiver 42 outputs a control signal 44 as long as the signal 54 is being received, and s the switch 47 remains closed, providing current I to deliver the therapeutic agent 36 through the patient's skin 40.
In the embodiment of Fig. 1, the agent 36 is contained in the electrode 34 connected as an anode. Other embodiments may be used, in ,o which the agent to be delivered is contained in the cathodic electrode 38, or wherein agents are contained in both electrodes. The power source 26 is shown as a battery with only a single direct current (DC) voltage supply.
It is contemplated that the power source 26 could be a combination of DC and/or alternating current (AC) sources providing complex DC and/or AC
,s waveforms or a combination of DC levels and/or ramps as desired:
The control of electrotransport current I, is shown as a simple switch 47 of switch means 32 whereby the "control" of current, l, is simply one of on or off. Besides a simple on/off type of current control, it is contemplated zo that more complex control over the magnitude, polarity, waveform shape, pulsing frequency, duty cycle, etc. of the current I and dosing time may be obtained by using more complex electrotransport circuits as described below.
The switch means 32 can include a magnetically actuated reed switch is in place of or in addition to the switch 47 for_ controlling the current, I. Reed switches have been used in implanted devices such as cardiac pacemakers.
See, for example, Alferness et al, US Patent 4,066,086;
Berntson US Patent 4,676,248; Hartlaub et al, US Patent 4,401,120, and Bowers US Patent 3,311,111. A magnetically activated reed switch provides so an added means of redundancy for preventing unwanted radiated signals from causing ~''' _nlf._.~~
W096113302 ~ ~ ~.~ PCTI1TS95f1321$
inadvertent drug delivery by ensuring that the current, l, is not delivered unless the reed switch is closed. This can be accomplished by passing a sufficiently strong magnet leg, in the form of a magnetic wand] over the delivery unit 24 during transmission of signal 54. Once the signal 54 is s received by the delivery unit 24, the magnetic wand may be removed from its position over the unit 24 to open the reed switch to ensure that extraneous radiafed energy signals have no effect on the subsequent operation of unit 24.
io Similarly, with reference to Fig. 4, a magnetically actuated reed switch (not shown] can be connected in series with the connection between the OUT signal of DRtI 168 and the IRQ1' signal of DMGU 160. In this case, programming signals transmitted by the transmitter GTS 154 have no effect on the programmiri~ of drug delivery by the delivery unit 130, unless the is reed switch is closed. Closure of the reed switch is accomplished by passing a magnet leg, a magnefic wand) of sufficient strength in close proximity with the reed switch. Rgain, this provides an additional margin of safety and immunity to extraneous radiated signals. -zo The delivery unit 24 may be mounted on the patients' body by conventional means, such as s#raps (not shown] aftached to the delivery unit 24 and encircling the trunk or limb of the patient. Alternatively, the delivery unit 24 may be attached to the patients' skin by means of adhesive film around the periphery of the electrodes 34, 38. An "in-line" adhesive on the zs skin-contacting surfaces of electrodes 34, 38, which adhesive is permeable to the therapeutic agent 36 and other ions under the influence of the applied electric potential, may also be used to attach the delivery unit 24 to the patients' skin 40.
,r-.j ~. ~:,. ..., WO 96113302 ~" ' ~ ~ '~ '~ ~ PCT/US95I13218 The physical separation and electric isolation between the control unit 22 and fhe delivery unit 24 provides much greater freedom in terms of separately mounting the control 22 and delivery unit 24. The delivery unit 24 may be mounted anywhere on the patient's back, neck, shoulders, head, s buttocks, back of legs, under arm or other areas not easily observed or reached. The control 22 unit may be kept in any convenient location, such as strapped to the patient's wrist, in a pocket or pocketbook or elsewhere.
io Radiated energy signals 54 of different types are contemplated for use in accordance with this invention. One preferred embodiment of this invention uses radio frequency (RF) signals 54 for the transmitter 50 and receiver 42 of the telemetry fink. Radio frequency signals may be modulated by amplitude modulation (AM), frequency modulation (FM), frequency shift is keying (FSK), phase shift keying (PSK) and the like. There is generally a trade off between modulation complexity and transmitter power consumption.
AM is generally simpler but less efFcient in terms of transmission range for a given power supply drain and signal to noise ratio (SNR). FM, FSK and PSK
are progressively more efficient for power supply drain and SNR
za considerations but require progressively more complex modulation circuits.
One useful reference regarding RF modulation methods is fhe Electronics Engineers Handbook, 3rd edition, Fink et al, McGraw Hill, New York, NY, 1989, chapter 14.
zs While the present invention is not limited to any particular frequency range, the frequency range of operation for the RF transmission is typically between about 1 MHz and 1000 MHz. One preferred frequency is about 310 MHz, corresponding to the industrial frequency band.
N ' ~ f~j .; J
WO96l13302 ~ ~ PCT'ltlS9i/13218 While the present invention is not limited to any particular power level for transmitter 50, a power level of up to 100 mW in accordance with I=CC regulations is contemplated for patient operated control units (ie, in those cases where the person operating the control unit is also s wearing the delivery unit). In one embodiment, a range of operation of up to about one meter was obtained with only 0.1 mW of transmitter power at a frequency of 310 MHz using coiled antennas (not shown) of about 2.5 cm diameter for the receiver 42 and about 5 cm diameter for the transmitter 50. A range of up to about 8 meters was obtained with a ~o transmitter poweuof about 100 mW and similar antenna sizes.
in other eriibodiments of the present invention, it is cantemplafed that the range of operation beturreen the control unit 22 and the delivery unit 24 may be extended up to hundreds or even thousands of kilometers, by ,s selecting appropriate communication channels having relay links such as cellular phone networks, satellite communication links and the like.
Limiting transmitter power for the control unit 22 is not of as great concern, as the size of the control unit 22 is under fewer constraints than the so size of the delivery unit 24 and therefore the control unit 22 can be made larger to accommodate larger sized batteries (in the case of a hand-held, patient-activated control unit 22), ar be in the form of a table or desk sized control unit 22 which is plugged into a standard electrical outlet (in the case of a control unit 22 for controlling delivery units 24 wom by zs patients in a hospital ward), or be in the form of a control unit utilizing large tower-sized transmitting antenna (in the case of a control unit 22 for controlling th~=~ delivery units 24 of patients located in a particular geographic region, eg, a cityor county).
r~ ~ .~., G. I ~~ ~ ..~ ..~ i' WO 96!13302 PCTIUS95/13218 Another radiated energy signal 54 contemplated for use in accordance with this invention is electromagnetic induction (EMI) using coupled coils (not shown). The coupling of radiated signals between coupled coils is determined by the mutual inductance of the coils. Calculations for the s mutual inductance of coils are shown in the US Bureau of Standards Circular C74, US Government Printing Office, and Bulletin of the Bureau of Standards Val. 8 printed 1912 and Vol. 18 printed 1918. Suitable coupled coils may be selected far transmission of radiated energy signals over a desired distance.
~o Yet another radiated energy signal contemplated for use in accordance with this invention, are ultrasonic waves transmitted and received by means of ultrasonic transducers. Infrared (IR) emitters and detectors may be used for radiated energy signal transmission in accordance ~s with this invention.
With reference to Figs. 2, 3 and 4, there is shown a particular embodiment of an electrotransport system having a telemetry link between control and delivery units in accordance with this invention and indicated zo generally by the numeral 100. In Fig. 2, a control unit 102 includes control buttons 104, 106, 108, and 110, an indicator LED 112 and an audio annunciator 114, such as a speaker or piezoelectric transducer. The control unit 102 transmits a radiated energy signal 120, by actuation of buttons 104-110 as explained below, to a delivery unit 130. Delivery unit 130 is 2s positioned on the skin of a patient (not shown) by means well known in the art, such that electrotransport electrodes 132 and 134 are in contact with the patient's skin The unit 130 provides electrotransport current, under control of the signal 120 as described below, to the electrodes 132 and 134 such that a therapeutic agent 136 contained in electrotransport electrode 132 is so delivered as desired.
ADO 9b113302 , ~ ~ ~:, ~ PCTIUS95f 13218 #~ ~ ~ ~ ~' ,.? t With reference to Fig. 3, there is depicted the delivery unit 130 transmitting a radiated response signal 122 to the control unit 102. The delivery unit 13D transmi#s the response signal 122 fo the control unit 102 under predetermined conditions described below. The control unit 102 is s configured to respond to the response signal 122 by displaying a predetermined sequence of lights on the LED 112. The control unit 102 may also be configured to respond to the response signal 122 by emitting a sequence of sounds or tones from the audio annunciator 114. In an alternate embodiment of the control unit 102, the audio annunciator 114 may be io replaced by an LCD or LED display unit configured to display alphanumeric information resulting from the response signal 122.
With reference to Fig. 4, there is shown a schematic diagram of the electrotransport sysfem 100 of Fig. 2 and 3, illustrating a preferred ~5 embodiment of a remote telemetry fink between control unit 102 and delivery unit 130 for i:rogramming and control in accordance with this invention.
The control unit 102 includes a micro-controller unit (MCU) 150, a first remote-control transmitterlreceiver unit (CTU) 152, a control transmitter stage so (CTS) 154, a second remote-control receiver unit (CRU) 156, and a control receiver stage (CRS) 158. Indicator devices, such as audio annunciator 114 and LED 112, are also included fot communicating system and/or patient state: information to an operator. Power and ground connections to the individu~i components are made in a suitable conventional manner.
One implementation of the present invention uses a MC68HC7051C1 ('705) 8-bit micro-controller, available from Motorola Semiconductor Products, Inc., Phoenix, Arizona for the MCU 150. The '705 includes an on-chip memory-with 504 bytes of erasable, programmable ROM (EPROM), ao 32 bytes of User RAM and a 64-bit EPROM. The'~05 may be programmed to provide desired output signals on the bidirectional, software programmable ~!'lU.'r WO 96f13302 PCTIUS95113218 pins, PA6, PA3, and PA4, and to respond to inputs on the bidirectional pins IRQ\, PAO, PA1, PA2, PAS, PA7, PBO. Switches 104, 106, 108, 110 provide inputs to pins IRO\, PAO, PA1 and PA2, respectively.
s The pin PA3 is configured as an output and connects to the audio annunciator 114. The pin PA4 is conftgured as an output and connects to the LED 112_ The annunciator 114 and LED 112 are provided with suitable connections to the system ground of the control unit 102.
~a In one implementation, the MCU 150 is programmed to treat the IRQ1 input as an interrupt. A logic low level on the IRO\ input puts the MCU 150 in a state waiting for succeeding switch actuation on inputs 106, 108, 110 to perform desired operations as described below.
~5 The CTU 152 and GRU 156 are each TMS3637 ('3637) programmable remote-control transmitterlreceiver units available from Texas Instruments, Dallas TX. The '3637 is a remote-control transmitter/receiver. The '3637 contains 31 bits of EPROM. These 31 bits can be programmed into two groups: 22 bits to store a unique code, and 20 9 bits to configure the '3637 as either a transmitter or a receiver. The total number of combinations for the stored code is 222 or 4,194,304 combinations. The CTU 152 and CRU 156 are programmed with different codes so that transmission of signals by CTS 154 and receipt of signals by CRS 158 may be securely differentiated as described in more detail below.
When the "3637 operates as a receiver, it can identify the 22-bit code for which it is programmed and consequently generates one pulse or toggles the state of an output pin, OUT. When the '3637 operates as a transmitter, it emits 22 bits of code when triggered by an external command or so continuously as tang as power is applied. The programming method is R d ~~
Wo96113302 ~' ~ ) ~) N° ...~ ~ PCTlUS95J1321$
described in the TMS3637 data sheet available from the Texas Instruments, Dallas, TX herein incorporated by reference.
The CTU 152 is programmed as a continuous mode transmitter, so s that a low level on the TIME input of CTU 152 causes a continuous transmission of the 22-bit control code on the OUT pin of CTU 152 as long as the CTU i 52 TIME input is low. Output PA6 of MCU 150 connects to the TIME input of CTU 152.
~o The I~IiCU 150 is programmed to cause the output PA6 to remain low for a period dependent on which of the switches 106, 108, 110 were selected after switch 104. For example, the PA6 output may be programmed to provide a low level for 5, 10 or 15 minutes, depending on the selection of switch 106, 108 or 110 respectively. The MCU 150 may also be 75 programmed toindicate which period was selected by flashing the LED 112 or beeping the annunciator 114 for a predetermined number of times, eg, 1, 2 or 3 for the 5, 10, or 15 minute period selected. This provides the operator with cohfirmation that the desired dosage time was selected.
zo The CTU 152 is programmed to output the transmitted code continuously on the OUT output of CTU 152. ThE CTLI 152 is driven at a suitable clock rate, for example, 5.7 kHz by a clock source (not shown).
The OUT signal drives the input of the CTS 154 transmitter. The CTS 154 is configured as a conventional low power AM transmitter consistent with zs FCC requlremehts to limit output power to 100 mW or less. The CT5 154 may be implemented with conventional printed circuit board and transistor technology as is uvell known in the art. A 2.5 cm microstrip antenna is a suitable transmitting antenna at a carrier frequency of,310 MHz.
A conventional transistor LC tuned collector circuit coupled to the microstrip so antenna {not shown) provides a suitable transmitter for amplitude modulation {AM) transmission in the CTS 154.
L ~ ~i''iJ.i.Jfl A base tuned transistor circuit (not shown) would also be a suitable transmitter stage for the CTS 154. For example, a Surtace Acoustic Wave resonator such as CW SAW oscillator available from R.F. Monolithics, Inc, Dallas, TX, may be used in the base circuit of a transmitter stage 154 and s modulated b', the OUT signal from CTU 152.
It is contemplated that frequency modulation (FM) would provide a lower power transmitting/receiving system for the electrotransport telemetry system 100 at this invention. It is further contemplated that Frequency Shift ~o Keying (FSKi. or Phase Shift Keying (PSK) would provide a still lower power transmittingireceiving system for the electrotransport telemetry system of this invention, at tfae expense of more complex modulating and demodulating circuitry.
~s The delivery unit 130 includes a delivery micro-controller (DMCU) 160, a delivery receiver stage (DRS} 164, a delivery transmitter stage (DTS) 166, a delivery remote-control receiver unit (DRU} 168, a delivery remote-control transmitter unit (DTU) 170, a current-control-unit (CCU) 172, a current-sense-unit (CSU), a series sense resistor, R, and electrotransport zo electrodes 13t and 134. The electrode 132 contains a suitable therapeutic drug or other agent 136 for delivery by electrotransport.
The DMCU 160 may be anofher MC68HC705K1 8-bit micro-controller and the DTU 'i l 0 and DRU 168 may be another pair of TMS3647 devices zs configured as a remote-control transmitter and receiver, respectively.
A low voltage power source, such as one or more 3-volt lithium coin cell batteries (~sAn02/Li) or the like may be used as the power supply for the delivery unit 130. Lithium coin cells are well known in the art and are so available from several commercial sources, such as Panasonic, Matsushita, WO96l13302 ;'1 "" '~ j PCl'lUS95II3218 '.'~ ~U ~i .J
and Duracell. Power and ground connections for the control unit 130 are made in a conventional manner.
The DRS 164 receives the signal 120 from the CTS 154 transmitter.
s The DRS 16~t is configured as an AM receiver to amplify, detect and demodulate the signal 120 and convert it to an output signal connected to the remote-control receiver unit DRU 168. The output signal from the DRS 164 is connected to the TIME input of the DRU 168. DRU 168 is programmed as a Valid Transmission Receiver (VTR) as described in the ,o TMS3637 data street, op cit. The VTR programmed DRU 168 is responsive to the same code transmitted by the CTS 154. The VTR response is programmed to produce a high level signal on the OUT pin of the DRU 168 as long as the transmitted signal 120 continues to provide the transmitted 22-bit code. The OUT pin of DRU 168 is connected to the IRQ\' pin of the ,s DMCU 160. The IRQ\' pin of DPJICU 160 is programmed to generate a high !eve! output on the PA7' pin as song as the OUT logic level fram DRU 168 is high. The high level on PA1' corresponds to a demand for delivery of electrotransport current, I.
as The output PA1' of DMCU 160 connects to an input 176 of the electric current supply unit (ECU) 172. The ECU 172 may be configured as a constant (or non-constant) current source responsive to a high level on the input 176. The ECU 172 includes a source current output connection 178 and source currenf return connection 180. The ECU 172 is adapted to 25 provide sufficient current. 1, to drive the therapeutic agent 136 contained in electrode 132 into the patients' skin. The return electrode 134 is connected to one side of the sense resistor R. The other side of the sense resistor R
provides a return path for the current I to the return connection 180 of ECU 172.
The current sense unit (CSU) 174 is connected across the sense resistor R by sense pins 182 and 184. The CSU 174 is configured to provide a hioh level signal on output 186 if the current I through the resistor R produces a voltage less than a predetermined amount for the dose rate s desired. This may 'occur if the resistance of the patients' skin is too high such that the CSU 174 comes out of compliance or the electrodes become dislodged from the skin. In either case the ECU. 172 will not be able to supply the necessary current and the desired dose will not be delivered.
The output 186 is connected to an input PA2' of DMCU 160. The PA2' input ,o is programmed as an active high input. In the event that CSU 174 senses the current, I ,is not in compliance, the high level output signal 186 is received by the DMCU 160 input PA2'.
A mope detailed description of a suitable electrical current source ~ s ECU 172 and current sense unit CSU 174 may be found in European Patent EP 0781152, published April 4, 1996.
zo The DMCU 160 is programmed to provide a low level on an output PA6' when the input signal PA2' from output signal 186 is a high level and the PA1' signal is high. This indicates that the desired electrotransport current, I, is not being delivered as desired.
zs Output PA6' connects to the TIME input of the DTU 170.
The DTU 1 r a is configured as a remote-control transmitter as described in the TMS363 i data sheet op cit. The DTU 170 is programmed to transmit a second 22-bit coded signal on the DTU 170 OUT pin when the Time input of DTU 170 is low. The second coded signal on OUT pin of .DTU 170 is so connected t~ an input of DTS 166. DTS 166 may also be configured as an AM transmitT~~~ stage converting the OUT signal, 170 to an AM modulated RF
{ .: -4 ,,-..
WO96l1330Z 1-' i '~ ~-J ..~ PCT/US9il13218 signal 122 at a suitable carrier frequency of about 310 MHz. DTS 166 modulates the second 22-bit coded OUT signal 170 and Transmits the second coded RF signal 122.
s The second coded RF signal 122 is received by CRS 158 of the control unit 1 U2. CRS 158 is configured as an AM receiver to detect, demodulate and amplify the received RF signal 122 and present the demodulates. output to the TIME input of CRU 15&.
to The CRU 156 is configured as a receiver, as described in the TMS3637 data sheet, responsive to The same code programmed in the DTU 170. Upon receiving the demodulated second coded signal 122 from CRS 158, CR'J 156 provides an output on the OUT pin of CRU 156.
The OUT pirt of CRU 156 connects to another programmed input pin of the 15 MCU 150, fer example, PA7. The input PA7 of the MCU 150 is programmed to be an input responsive to the OUT signal of CRU 156.
The MCU 150 is programmed fo provide an indication to the operator that the current, I, is-not in compliance by toggling the pins PA3 and PA4 (hereby flashing the !_FD 112 andlor sounding the annunciator 114 with a zo predetermined pattern, The operator may then act appropriately by checking the connection of the electrodes 132 and 134, or locating them to an area which makes better contact with the patient's skin.
From the foregoing description of the sense resistor R, ECU 172, zs CSU 174 and DhiiCU 160, those skilled in the art wilt readily appreciate that any number of patient body parameter conditions andlor delivery unit 130 conditions can be checked and transmitted to the remote control unit by means of D T S 166 and CRS 158. For example, means for sensing a body parameter such as a thermometer for sensing body temperature, a piezo a~ electric device for sensing body or muscle movement, a.blood glucose sensing element; and/or a blood gas sensing element may be substituted for W0 96113302 G i ~~ ~ .! .l ~ PCTlUS95113218 the sense resistor R and associated circuitry in order to provide other types of sense signals relating to the particular parameter being sensed. In addition, me<jns for sensing a parameter of the delivery unit 130 may also be sensed and transmitted in a similar fashion. For example, a counter which s counts the number of doses delivered from the delivery unit 130 may transmit this dosing information. Other system parameters such as battery strength, amount of therapeutic agent remaining to be delivered, whether the delivery unit is currently operating in an "on" or an "off' mode, and whether or not a system malfunction has occurred could also be sensed by an to appropriate sensing means and transmitted via the transmitting and receiving means.
In other embodiments of the electrotransport telemetry system in accordance with this invention, MCU 150 may be programmed with a ~5 plurality of control programs, as is well known in the art. The plurality of programs, may include providing multiple patterns of delivery. For example, one program may provide an output signal on the PA6 output to the TIME
input of the CTU 152 having a sequence of predetermined periods such as 10 minutes of delivery followed by 50 minutes of non-delivery. This pattern zo may be repeated by a desired number of repetitions, as programmed.
Any number of delivery profiles may be programmed into MCU 150.
Alternatively, a program may choose different delivery and non delivery intervals and repetition sequences to be selected by differing actuation of the input switches 104 - 110.
The MCU 150 may also be programmed to react in predetermined fashion to signals received from the CRS 158 and CRU 156. For example, one program may provide alternative display patterns on the annunciafor 114 ar LED 112 in response to signals transmitted by DTS 166 and DTU 170, by ao flashing or sounding at a rapid rate to indicate an abnormal condition (eg, too low cr too high a drug delivery rate) regarding the drug delivery.
R'O 96113302 ~ ~ '~ ~ J .: ~ PCT/1IS95113218 It is contemplated that the embodiments of the invention may be combined in various combinations to provide, for example, a dosage regimen having a predetermined pattern customized by the physician fior a particular patient, that is programmed into the control unit 102.
s The inputs IRQ\, PAO, PA1, PA2, of the control unit 102, connected to control switches 104-110, could be programmed to provide different optional dosage patterns on patient demand. The delivery unit 130 could be configured with different sensor osrcuitry having signals responsive to other ~o conditions, such as the oxygen or carbon dioxide content of the patient's tissue, hear rate, skin impedance, skin temperature and the like. These signals may be fed back to the control unit 102 by means of the telemetry link of this invention providing a compact delivery unit in a system having improved performance. Other embodiments of this invention incorporating 1s numerical di~,plays, such as multiplexed LCD displays connected to the MCU 150, are contemplated as within the scope afthe claims.
While the foregoing detailed description has described an embodiment of the electrotransport system having a telemetry ii~k communicating zo between contras and delivery units in accordance with this invention, it is to be understecd that the above description is illustrative only and not limiting of the disclosed invention. It will be appreciated that it would be possible to modify the number and type of control circuits and delivery circuits, the materials and methods of construction and the logic forms and zs interconnections or to include or exclude various elements within the scope and spirit of the invention. Thus the invention is to be limited only by the claims as set forth below.
Claims (21)
1. In an electrotransport system (20) for delivering a therapeutic agent (36) through a body surface (40) of a patient, the system (20) including a delivery unit (24) having a pair of electrodes (34, 38), at least one of the electrodes (34, 38) containing the therapeutic agent (36) to be delivered, a source of electrical power (26) electrically connectable to the electrodes (34. 38), and a control unit (22) for communicating with the delivery unit (24), the system (20) being characterized by:
the delivery unit (24) being physically remote from the control unit (22); and a telemetry communication link (50, 54, 42) between the delivery and control units whereby the units (24, 22) communicate by means of a radiated energy signal (54) transmitter means (50) and receiver means (42).
the delivery unit (24) being physically remote from the control unit (22); and a telemetry communication link (50, 54, 42) between the delivery and control units whereby the units (24, 22) communicate by means of a radiated energy signal (54) transmitter means (50) and receiver means (42).
2. The electrotransport system of claim 1, wherein the control unit (22) comprises the transmitter means (50) and the delivery unit (22) comprises the receiver means (42).
3. The electrotransport system of claim 1, wherein the delivery unit (24) comprises the transmitter means (50) and the control unit (22) comprises the receiver means (42).
4. The electrotransport system of claim 1, wherein the delivery unit (24) comprises both a radiated energy signal transmitter means (50) and receiver means (42) and the control unit (22) comprises both a radiated energy signal transmitter means (50) and receiver means (42).
5. The electrotransport system of claim 1, wherein the control unit (22) controls an electrotransport current (I) applied to the patient.
6. The electrotransport system of claim 1, wherein the control unit (22) is to mount on a wrist of the patient.
7. The electrotransport system of claim 1, wherein the control unit (22) is to operate and transmit the radiated energy signal (54) to the receiver means (42) from a distance in a range of more than 1,000 kilometers.
8. The electrotransport system of claim 1, wherein, a manually operated switch (46) provides an input to the transmitter means (50).
9. The electrotransport system of claim 1, wherein the control unit (22) includes a microprocessor having an output connected to the transmitter means (50). the microprocessor having a plurality of stored programs for providing a corresponding plurality of radiated energy signals; and means for selecting one of said stored programs;
whereby the delivery of the therapeutic agent is remotely controlled according to the radiated energy signal corresponding to the selected program.
whereby the delivery of the therapeutic agent is remotely controlled according to the radiated energy signal corresponding to the selected program.
10. The electrotransport system of claim 1, wherein the transmitter means (50) and receiver means (42) are to communicate by radio frequency radiated energy.
11. The electrotransport system of claim 10, wherein the radio frequency radiated energy has a frequency of 1 MHz to 1000 MHz.
12. The electrotransport system of claim 10, wherein the radio frequency radiated energy is modulated by a modulation method selected from the group consisting of amplitude modulation, frequency modulation, frequency shift keying, and phase shift keying.
13. The electrotransport system of claim 1, wherein the transmitter means (50) and receiver means (42) are to communicate by a form of radiated anergy selected from the group consisting of ultrasonic, optical, infrared and electromagnetic induction energies.
14. The electrotransport system of claim 1, wherein the transmitter means (50) includes a coding means for coding the transmitted signals (54) and the receiver means (42) includes a decoding means for decoding the received signals (54).
15. The electrotransport system of claim 1, wherein the delivery unit (130) includes:
a sensor means (174) for sensing a predetermined patient body parameter condition, the sensor means (174) providing a sense signal (186);
radiated energy return transmitter means (166), responsive to the sense signal (186), for transmitting a return radiated energy signal (122);
and the control unit (102) includes a receiver and display means (158, 112, 114) for receiving the return radiated energy signal (122) and providing a display (112, 114) of the body parameter condition.
a sensor means (174) for sensing a predetermined patient body parameter condition, the sensor means (174) providing a sense signal (186);
radiated energy return transmitter means (166), responsive to the sense signal (186), for transmitting a return radiated energy signal (122);
and the control unit (102) includes a receiver and display means (158, 112, 114) for receiving the return radiated energy signal (122) and providing a display (112, 114) of the body parameter condition.
16. The electrotransport system of claim 15, wherein the sensor means (174) is to sense a body parameter selected from the group consisting of breathing rate, body temperature, muscle movement, blood glucose concentration, sweat response, skin resistance, heart rate, tissue oxygen content. tissue carbon dioxide content, patient emergency condition and body motion.
17. The electrotransport system of claim 15, wherein the display means (112. 114) is selected from the group consisting of a light emitting diode. a liquid crystal display, an audio annunciator, a cathode ray tube display, a video screen and a printer.
18. The electrotransport system of claim 1, wherein the delivery unit includes:
a sensor means for sensing a predetermined electrotransport system parameter condition, the sensor means providing a sense signal;
radiated energy return transmitter means, responsive to the sense signal. for transmitting a return radiated energy signal; and the control unit includes a receiver and display means for receiving the return radiated energy signal and providing a display of the system parameter condition.
a sensor means for sensing a predetermined electrotransport system parameter condition, the sensor means providing a sense signal;
radiated energy return transmitter means, responsive to the sense signal. for transmitting a return radiated energy signal; and the control unit includes a receiver and display means for receiving the return radiated energy signal and providing a display of the system parameter condition.
19. The electrotransport system of claim 18, wherein the sensor means is to sense a system parameter selected from the group consisting of therapeutic agent dosing history, amount of therapeutic agent remaining to be delivered, battery strength, geographic location of the device, whether the delivery unit is currently delivering therapeutic agent, and system malfunction.
20. The electrotransport system of claim 1, wherein the delivery unit (24) comprises a receiver means (42) for receiving a radiated energy signal (54) and providing a control signal (44) responsive to the radiated energy signal (54) and current control means (32, 46) to control an electrotransport current (I) applied by the delivery unit (24), the control means (32, 46) responsive to the control signal (44); and a control unit (22) comprises a transmitter means (50) for transmitting the radiated energy signal (54), whereby the electrotransport current (I) applied by the delivery unit (24) is controlled by the radiated energy signal (54) transmitted from the remote control unit (22).
21. The electrotransport system of claim 1, including a magnetically activated switch which when closed enables communication between the delivery and control units (24,22).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/332,322 US5551953A (en) | 1994-10-31 | 1994-10-31 | Electrotransport system with remote telemetry link |
US08/332,322 | 1994-10-31 | ||
PCT/US1995/013218 WO1996013302A1 (en) | 1994-10-31 | 1995-10-17 | Electrotransport system with remote telemetry link |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2198357A1 CA2198357A1 (en) | 1996-05-09 |
CA2198357C true CA2198357C (en) | 2005-08-16 |
Family
ID=23297717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002198357A Expired - Fee Related CA2198357C (en) | 1994-10-31 | 1995-10-17 | Electrotransport system with remote telemetry link |
Country Status (11)
Country | Link |
---|---|
US (1) | US5551953A (en) |
EP (1) | EP0789603B1 (en) |
JP (1) | JPH10507948A (en) |
KR (1) | KR100382860B1 (en) |
AT (1) | ATE314113T1 (en) |
AU (1) | AU691987B2 (en) |
CA (1) | CA2198357C (en) |
DE (1) | DE69534722T2 (en) |
DK (1) | DK0789603T3 (en) |
ES (1) | ES2250975T3 (en) |
WO (1) | WO1996013302A1 (en) |
Families Citing this family (181)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5876368A (en) * | 1994-09-30 | 1999-03-02 | Becton Dickinson And Company | Iontophoretic drug delivery device having improved controller |
SE9501678D0 (en) * | 1995-05-05 | 1995-05-05 | Siemens Elema Ab | Device for transmitting information via patient tube in intensive care or anesthesia apparatus |
US6086572A (en) * | 1996-05-31 | 2000-07-11 | Alza Corporation | Electrotransport device and method of setting output |
US5857994A (en) * | 1996-10-01 | 1999-01-12 | Becton, Dickinson And Company | Awakenable iontophoretic/delivery device for reducing electrical sensation upon application thereof |
US8734339B2 (en) * | 1996-12-16 | 2014-05-27 | Ip Holdings, Inc. | Electronic skin patch for real time monitoring of cardiac activity and personal health management |
US5991655A (en) * | 1997-03-03 | 1999-11-23 | Drug Delivery Systems, Inc. | Iontophoretic drug delivery device and method of manufacturing the same |
US5899876A (en) * | 1997-08-27 | 1999-05-04 | Becton, Dickinson And Company | Multiple site drug delivery system |
US20010009983A1 (en) * | 1997-09-29 | 2001-07-26 | Drug Delivery Technologies, Inc. | Methods for implementing current delivery profiles used in an iontophoretic system |
DE69835529T2 (en) * | 1997-11-03 | 2007-01-18 | Harris Corp., Melbourne | RECONFIGURABLE RADIO SYSTEM CONSTRUCTION |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US6454754B1 (en) * | 1998-10-29 | 2002-09-24 | Steven R. Frank | Respiratory infection treatment device |
IT1304052B1 (en) * | 1998-12-23 | 2001-03-07 | Fabio Paolo Marchesi | ELECTRONIC STIMULATION EQUIPMENT WITH WIRELESS SATELLITE UNIT |
US6317630B1 (en) * | 1999-01-29 | 2001-11-13 | Yossi Gross | Drug delivery device |
US6477410B1 (en) | 2000-05-31 | 2002-11-05 | Biophoretic Therapeutic Systems, Llc | Electrokinetic delivery of medicaments |
US6792306B2 (en) | 2000-03-10 | 2004-09-14 | Biophoretic Therapeutic Systems, Llc | Finger-mounted electrokinetic delivery system for self-administration of medicaments and methods therefor |
US6553253B1 (en) * | 1999-03-12 | 2003-04-22 | Biophoretic Therapeutic Systems, Llc | Method and system for electrokinetic delivery of a substance |
US7171264B1 (en) * | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
EP1183068A4 (en) * | 1999-05-10 | 2008-12-17 | Gentronics Inc | Method of electroporation-enhanced delivery of active agents |
EP1180053A4 (en) * | 1999-05-17 | 2006-11-08 | Kevin S Marchitto | Remote and local controlled delivery of pharmaceutical compounds using electromagnetic energy |
US20040229295A1 (en) * | 1999-05-17 | 2004-11-18 | Marchitto Kevin S. | Activated delivery of biomolecules using electromagnetic energy |
US6312612B1 (en) | 1999-06-09 | 2001-11-06 | The Procter & Gamble Company | Apparatus and method for manufacturing an intracutaneous microneedle array |
US6379324B1 (en) | 1999-06-09 | 2002-04-30 | The Procter & Gamble Company | Intracutaneous microneedle array apparatus |
US6256533B1 (en) * | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
WO2000078207A2 (en) * | 1999-06-22 | 2000-12-28 | The Secretary Of State For Defence | Analyte detection |
US6334859B1 (en) | 1999-07-26 | 2002-01-01 | Zuli Holdings Ltd. | Subcutaneous apparatus and subcutaneous method for treating bodily tissues with electricity or medicaments |
US6969382B2 (en) * | 1999-07-26 | 2005-11-29 | Zuli Holdings, Ltd. | Method and apparatus for treating bodily tissues with medicinal substance |
US6361522B1 (en) * | 1999-10-21 | 2002-03-26 | Cardiac Pacemakers, Inc. | Drug delivery system for implantable cardiac device |
AU3081601A (en) * | 1999-11-15 | 2001-05-30 | Velcro Industries B.V. | Skin attachment member |
US6310556B1 (en) * | 2000-02-14 | 2001-10-30 | Sonic Innovations, Inc. | Apparatus and method for detecting a low-battery power condition and generating a user perceptible warning |
US6714816B1 (en) * | 2000-02-22 | 2004-03-30 | University Of South Florida | Electroporation and electrophoresis system and method for achieving molecular penetration into cells in vivo |
US6565532B1 (en) | 2000-07-12 | 2003-05-20 | The Procter & Gamble Company | Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup |
US6699188B2 (en) | 2000-06-22 | 2004-03-02 | Guidance Interactive Technologies | Interactive reward devices and methods |
AU2001283359A1 (en) * | 2000-08-14 | 2002-02-25 | Pharmacia Corporation | Drug release (delivery system) |
US7623926B2 (en) | 2000-09-27 | 2009-11-24 | Cvrx, Inc. | Stimulus regimens for cardiovascular reflex control |
US8086314B1 (en) | 2000-09-27 | 2011-12-27 | Cvrx, Inc. | Devices and methods for cardiovascular reflex control |
US7499742B2 (en) | 2001-09-26 | 2009-03-03 | Cvrx, Inc. | Electrode structures and methods for their use in cardiovascular reflex control |
US7840271B2 (en) | 2000-09-27 | 2010-11-23 | Cvrx, Inc. | Stimulus regimens for cardiovascular reflex control |
US7616997B2 (en) | 2000-09-27 | 2009-11-10 | Kieval Robert S | Devices and methods for cardiovascular reflex control via coupled electrodes |
US8715177B2 (en) | 2000-10-06 | 2014-05-06 | Ip Holdings, Inc. | Intelligent drug delivery appliance |
US7131987B2 (en) * | 2000-10-16 | 2006-11-07 | Corium International, Inc. | Microstructures and method for treating and conditioning skin which cause less irritation during exfoliation |
US7108681B2 (en) | 2000-10-16 | 2006-09-19 | Corium International, Inc. | Microstructures for delivering a composition cutaneously to skin |
US7828827B2 (en) * | 2002-05-24 | 2010-11-09 | Corium International, Inc. | Method of exfoliation of skin using closely-packed microstructures |
US6748089B1 (en) | 2000-10-17 | 2004-06-08 | Sonic Innovations, Inc. | Switch responsive to an audio cue |
US7369890B2 (en) | 2000-11-02 | 2008-05-06 | Cardiac Pacemakers, Inc. | Technique for discriminating between coordinated and uncoordinated cardiac rhythms |
US6689117B2 (en) | 2000-12-18 | 2004-02-10 | Cardiac Pacemakers, Inc. | Drug delivery system for implantable medical device |
WO2002049509A2 (en) * | 2000-12-21 | 2002-06-27 | Insulet Corporation | Medical apparatus remote control and method |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
AU2002245675A1 (en) * | 2001-03-13 | 2002-09-24 | University Of South Florida | Electromanipulation device and method |
US6663820B2 (en) * | 2001-03-14 | 2003-12-16 | The Procter & Gamble Company | Method of manufacturing microneedle structures using soft lithography and photolithography |
DK1390099T3 (en) * | 2001-04-27 | 2008-06-09 | Transport Pharmaceuticals Inc | System for electrokinetic delivery of substance |
US20050182389A1 (en) * | 2001-04-30 | 2005-08-18 | Medtronic, Inc | Implantable medical device and patch system and method of use |
US6591124B2 (en) | 2001-05-11 | 2003-07-08 | The Procter & Gamble Company | Portable interstitial fluid monitoring system |
US7209783B2 (en) * | 2001-06-15 | 2007-04-24 | Cardiac Pacemakers, Inc. | Ablation stent for treating atrial fibrillation |
US7493162B2 (en) * | 2001-06-15 | 2009-02-17 | Cardiac Pacemakers, Inc. | Pulmonary vein stent for treating atrial fibrillation |
US20040087992A1 (en) * | 2002-08-09 | 2004-05-06 | Vladimir Gartstein | Microstructures for delivering a composition cutaneously to skin using rotatable structures |
US7340303B2 (en) | 2001-09-25 | 2008-03-04 | Cardiac Pacemakers, Inc. | Evoked response sensing for ischemia detection |
JP2005511079A (en) * | 2001-12-06 | 2005-04-28 | バイオ−ラッド ラボラトリーズ,インコーポレイティド | Automatic electroporation optimization system |
US7493168B2 (en) * | 2002-02-01 | 2009-02-17 | The Cleveland Clinic Foundation | Electrical stimulation to treat hair loss |
US7483736B2 (en) * | 2002-04-24 | 2009-01-27 | Rocky Mountain Biosystems, Inc. | Feedback control device for transcutaneous drug delivery and uses therefor |
WO2003092764A2 (en) * | 2002-04-29 | 2003-11-13 | Kevin Marchitto | Controlled release transdermal drug delivery |
US6761561B2 (en) | 2002-06-07 | 2004-07-13 | Schick Technologies | Wireless dental camera |
US7089055B2 (en) * | 2002-06-28 | 2006-08-08 | Cardiac Pacemakers, Inc. | Method and apparatus for delivering pre-shock defibrillation therapy |
US6972411B2 (en) * | 2002-10-03 | 2005-12-06 | Schick Technologies, Inc. | Method of event detection for intraoral image sensor |
US7072443B2 (en) * | 2002-10-03 | 2006-07-04 | Schick Technologies, Inc. | Intraoral image sensor |
US7072711B2 (en) | 2002-11-12 | 2006-07-04 | Cardiac Pacemakers, Inc. | Implantable device for delivering cardiac drug therapy |
US20050058701A1 (en) * | 2003-01-29 | 2005-03-17 | Yossi Gross | Active drug delivery in the gastrointestinal tract |
US20040267240A1 (en) * | 2003-01-29 | 2004-12-30 | Yossi Gross | Active drug delivery in the gastrointestinal tract |
KR20050098277A (en) * | 2003-01-29 | 2005-10-11 | 이-필 파마 리미티드 | Active drug delivery in the gastrointestinal tract |
US6908307B2 (en) | 2003-02-03 | 2005-06-21 | Schick Technologies | Dental camera utilizing multiple lenses |
US7578954B2 (en) * | 2003-02-24 | 2009-08-25 | Corium International, Inc. | Method for manufacturing microstructures having multiple microelements with through-holes |
US7320675B2 (en) | 2003-08-21 | 2008-01-22 | Cardiac Pacemakers, Inc. | Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure |
DE10354833A1 (en) * | 2003-11-24 | 2005-06-23 | Liedtke, Rainer K., Dr. | Dermal diagnostic patch systems with active transponders |
US8017145B2 (en) * | 2003-12-22 | 2011-09-13 | Conopco, Inc. | Exfoliating personal care wipe article containing an array of projections |
US7840263B2 (en) | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
US8024033B2 (en) | 2004-02-27 | 2011-09-20 | Encore Medical Asset Corporation | Iontophoretic electrode |
WO2005094526A2 (en) | 2004-03-24 | 2005-10-13 | Corium International, Inc. | Transdermal delivery device |
US7857767B2 (en) | 2004-04-19 | 2010-12-28 | Invention Science Fund I, Llc | Lumen-traveling device |
US7850676B2 (en) | 2004-04-19 | 2010-12-14 | The Invention Science Fund I, Llc | System with a reservoir for perfusion management |
US8361013B2 (en) | 2004-04-19 | 2013-01-29 | The Invention Science Fund I, Llc | Telescoping perfusion management system |
US7998060B2 (en) | 2004-04-19 | 2011-08-16 | The Invention Science Fund I, Llc | Lumen-traveling delivery device |
US9801527B2 (en) | 2004-04-19 | 2017-10-31 | Gearbox, Llc | Lumen-traveling biological interface device |
US9011329B2 (en) | 2004-04-19 | 2015-04-21 | Searete Llc | Lumenally-active device |
US8092549B2 (en) | 2004-09-24 | 2012-01-10 | The Invention Science Fund I, Llc | Ciliated stent-like-system |
US8337482B2 (en) | 2004-04-19 | 2012-12-25 | The Invention Science Fund I, Llc | System for perfusion management |
US8353896B2 (en) * | 2004-04-19 | 2013-01-15 | The Invention Science Fund I, Llc | Controllable release nasal system |
US8019413B2 (en) | 2007-03-19 | 2011-09-13 | The Invention Science Fund I, Llc | Lumen-traveling biological interface device and method of use |
US7764995B2 (en) | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
US7567841B2 (en) | 2004-08-20 | 2009-07-28 | Cardiac Pacemakers, Inc. | Method and apparatus for delivering combined electrical and drug therapies |
GB0419238D0 (en) * | 2004-08-28 | 2004-09-29 | Univ Manchester | Dysphagia recovery |
US7205701B2 (en) * | 2004-09-03 | 2007-04-17 | Honeywell International Inc. | Passive wireless acoustic wave chemical sensor |
US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
US8060219B2 (en) | 2004-12-20 | 2011-11-15 | Cardiac Pacemakers, Inc. | Epicardial patch including isolated extracellular matrix with pacing electrodes |
US7499748B2 (en) | 2005-04-11 | 2009-03-03 | Cardiac Pacemakers, Inc. | Transvascular neural stimulation device |
US7617003B2 (en) * | 2005-05-16 | 2009-11-10 | Cardiac Pacemakers, Inc. | System for selective activation of a nerve trunk using a transvascular reshaping lead |
WO2006123346A2 (en) * | 2005-05-19 | 2006-11-23 | E-Pill Pharma, Ltd. | Ingestible device for nitric oxide production in tissue |
US8386030B2 (en) | 2005-08-08 | 2013-02-26 | Tti Ellebeau, Inc. | Iontophoresis device |
US8295922B2 (en) | 2005-08-08 | 2012-10-23 | Tti Ellebeau, Inc. | Iontophoresis device |
US20070088331A1 (en) * | 2005-08-18 | 2007-04-19 | Transcutaneous Technologies Inc. | Method and apparatus for managing active agent usage, and active agent injecting device |
US20070088332A1 (en) * | 2005-08-22 | 2007-04-19 | Transcutaneous Technologies Inc. | Iontophoresis device |
US20090254018A1 (en) * | 2005-08-24 | 2009-10-08 | Mizuo Nakayama | Electrode assembly for freezing-type iontophoresis device |
WO2007032446A1 (en) | 2005-09-15 | 2007-03-22 | Tti Ellebeau, Inc. | Rod type iontophoresis device |
US7616990B2 (en) | 2005-10-24 | 2009-11-10 | Cardiac Pacemakers, Inc. | Implantable and rechargeable neural stimulator |
US20080015422A1 (en) * | 2005-12-29 | 2008-01-17 | Guidance Interactive Healthcare, Inc. | Combined peripheral and health monitoring devices |
US20070179356A1 (en) * | 2005-12-29 | 2007-08-02 | Guidance Interactive Healthcare, Inc. | Programmable devices, systems and methods for encouraging the monitoring of medical parameters |
US9220917B2 (en) | 2006-04-12 | 2015-12-29 | The Invention Science Fund I, Llc | Systems for autofluorescent imaging and target ablation |
US20120035438A1 (en) * | 2006-04-12 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Path selection by a lumen traveling device in a body tub tree based on previous path |
CN105468895A (en) | 2006-05-02 | 2016-04-06 | 普罗透斯数字保健公司 | Patient customized therapeutic regimens |
US7920907B2 (en) | 2006-06-07 | 2011-04-05 | Abbott Diabetes Care Inc. | Analyte monitoring system and method |
WO2007149811A2 (en) | 2006-06-19 | 2007-12-27 | Highland Instruments, Inc. | Apparatus and method for stimulation of biological tissue |
US9913976B2 (en) | 2006-06-19 | 2018-03-13 | Highland Instruments, Inc. | Systems and methods for stimulating and monitoring biological tissue |
US8718758B2 (en) * | 2006-06-19 | 2014-05-06 | Highland Instruments, Inc. | Interface apparatus for stimulation of biological tissue |
US9623241B2 (en) | 2006-06-19 | 2017-04-18 | Highland Instruments | Treatment methods |
WO2008027440A2 (en) * | 2006-08-29 | 2008-03-06 | Tti Ellebeau, Inc. | An iontophoresis device and method for operation with a usb (universal serial bus) power source |
KR101611240B1 (en) | 2006-10-25 | 2016-04-11 | 프로테우스 디지털 헬스, 인코포레이티드 | Controlled activation ingestible identifier |
JP5383497B2 (en) | 2006-12-01 | 2014-01-08 | Tti・エルビュー株式会社 | System and device for powering and / or controlling a device, for example a transdermal delivery device |
EP2121111B1 (en) | 2007-01-22 | 2018-03-14 | Corium International, Inc. | Applicators for microneedle arrays |
CA2676407A1 (en) | 2007-02-01 | 2008-08-07 | Proteus Biomedical, Inc. | Ingestible event marker systems |
CA2676280C (en) | 2007-02-14 | 2018-05-22 | Proteus Biomedical, Inc. | In-body power source having high surface area electrode |
US8911749B2 (en) | 2007-04-16 | 2014-12-16 | Corium International, Inc. | Vaccine delivery via microneedle arrays |
EP2146689B1 (en) | 2007-04-16 | 2020-08-12 | Corium, Inc. | Solvent-cast microneedle arrays containing active |
US20100145317A1 (en) * | 2007-04-19 | 2010-06-10 | Morris Laster | Device system and method for monitoring and controlling blood analyte levels |
US7998110B2 (en) * | 2007-04-25 | 2011-08-16 | Hong Kong Polytechnic University | Medical device for delivering drug and/or performing physical therapy |
US8540632B2 (en) | 2007-05-24 | 2013-09-24 | Proteus Digital Health, Inc. | Low profile antenna for in body device |
US7945320B2 (en) * | 2007-08-17 | 2011-05-17 | Isis Biopolymer, Inc. | Iontophoretic drug delivery system |
CA2708497A1 (en) * | 2007-12-10 | 2009-06-18 | Isis Biopolymer Llc | Iontophoretic drug delivery device and software application |
US8369942B2 (en) * | 2008-03-20 | 2013-02-05 | The Invention Science Fund I, Llc | Subdermal material delivery device |
ES2696984T3 (en) | 2008-07-08 | 2019-01-21 | Proteus Digital Health Inc | Ingestion event marker data infrastructure |
EP3120895A1 (en) * | 2008-12-30 | 2017-01-25 | Teva Pharmaceuticals International GmbH | Electronic control of drug delivery system |
WO2010080843A2 (en) | 2009-01-06 | 2010-07-15 | Proteus Biomedical, Inc. | Ingestion-related biofeedback and personalized medical therapy method and system |
JP5457042B2 (en) * | 2009-01-29 | 2014-04-02 | テルモ株式会社 | Transdermal drug delivery system |
US8414559B2 (en) | 2009-05-07 | 2013-04-09 | Rainbow Medical Ltd. | Gastroretentive duodenal pill |
US20100286587A1 (en) * | 2009-05-07 | 2010-11-11 | Yossi Gross | Sublingual electrical drug delivery |
US20110092881A1 (en) * | 2009-05-08 | 2011-04-21 | Isis Biopolymer Inc. | Iontophoretic device with contact sensor |
EP2427245A1 (en) * | 2009-05-08 | 2012-03-14 | Isis Biopolymer, Inc. | Iontophoretic device with improved counterelectrode |
DE202009012183U1 (en) * | 2009-09-08 | 2009-11-26 | Bürkert Werke GmbH & Co. KG | Manually actuable control module |
TWI517050B (en) | 2009-11-04 | 2016-01-11 | 普羅托斯數位健康公司 | System for supply chain management |
ES2719595T3 (en) | 2010-05-04 | 2019-07-11 | Corium Int Inc | Method and device for transdermal administration of parathyroid hormone using a microprojection matrix |
TWI557672B (en) * | 2010-05-19 | 2016-11-11 | 波提亞斯數位康健公司 | Computer system and computer-implemented method to track medication from manufacturer to a patient, apparatus and method for confirming delivery of medication to a patient, patient interface device |
US8509882B2 (en) | 2010-06-08 | 2013-08-13 | Alivecor, Inc. | Heart monitoring system usable with a smartphone or computer |
US9351654B2 (en) | 2010-06-08 | 2016-05-31 | Alivecor, Inc. | Two electrode apparatus and methods for twelve lead ECG |
WO2012054560A1 (en) | 2010-10-21 | 2012-04-26 | Highland Instruments, Inc. | Methods for detecting a condition |
US8428709B1 (en) | 2012-06-11 | 2013-04-23 | Incline Therapeutics, Inc. | Current control for electrotransport drug delivery |
US8428708B1 (en) | 2012-05-21 | 2013-04-23 | Incline Therapeutics, Inc. | Self-test for analgesic product |
US8301238B2 (en) | 2011-03-31 | 2012-10-30 | Incline Therapeutics, Inc. | Two-part electrotransport device |
US9238133B2 (en) | 2011-05-09 | 2016-01-19 | The Invention Science Fund I, Llc | Method, device and system for modulating an activity of brown adipose tissue in a vertebrate subject |
US8968377B2 (en) | 2011-05-09 | 2015-03-03 | The Invention Science Fund I, Llc | Method, device and system for modulating an activity of brown adipose tissue in a vertebrate subject |
WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
CN103827914A (en) | 2011-07-21 | 2014-05-28 | 普罗秋斯数字健康公司 | Mobile communication device, system, and method |
DE202012002019U1 (en) * | 2012-02-27 | 2012-04-03 | Bürkert Werke GmbH | Manually actuable control module |
US8761717B1 (en) | 2012-08-07 | 2014-06-24 | Brian K. Buchheit | Safety feature to disable an electronic device when a wireless implantable medical device (IMD) is proximate |
WO2014036436A1 (en) | 2012-08-30 | 2014-03-06 | Alivecor, Inc. | Cardiac performance monitoring system for use with mobile communications devices |
WO2014074913A1 (en) | 2012-11-08 | 2014-05-15 | Alivecor, Inc. | Electrocardiogram signal detection |
AU2013344818B2 (en) * | 2012-11-14 | 2017-04-27 | International Scientific Pty Ltd | A device, system, method, computer program and data signal for the control of a transdermal delivery device |
US11052231B2 (en) | 2012-12-21 | 2021-07-06 | Corium, Inc. | Microarray for delivery of therapeutic agent and methods of use |
WO2014107700A1 (en) | 2013-01-07 | 2014-07-10 | Alivecor, Inc. | Methods and systems for electrode placement |
FR3000897B1 (en) * | 2013-01-14 | 2016-10-28 | Feeligreen | AUTORGANIZED ELECTROSTIMULATION AND / OR IONTOPHORESIS DEVICE |
RU2674083C2 (en) | 2013-03-12 | 2018-12-04 | Кориум Интернэшнл, Инк. | Microprojection applicators |
WO2014145927A1 (en) | 2013-03-15 | 2014-09-18 | Alivecor, Inc. | Systems and methods for processing and analyzing medical data |
EP2968116A1 (en) | 2013-03-15 | 2016-01-20 | Corium International, Inc. | Microarray with polymer-free microstructures, methods of making, and methods of use |
ES2761580T3 (en) | 2013-03-15 | 2020-05-20 | Corium Inc | Microarrays for therapeutic agent delivery, methods of use and manufacturing methods |
AU2014233695A1 (en) | 2013-03-15 | 2015-10-01 | Corium International, Inc. | Microarray for delivery of therapeutic agent and methods of use |
WO2014150285A2 (en) | 2013-03-15 | 2014-09-25 | Corium International, Inc. | Multiple impact microprojection applicators and methods of use |
JP6511439B2 (en) | 2013-06-04 | 2019-05-15 | プロテウス デジタル ヘルス, インコーポレイテッド | Systems, devices, and methods for data collection and outcome assessment |
US9247911B2 (en) | 2013-07-10 | 2016-02-02 | Alivecor, Inc. | Devices and methods for real-time denoising of electrocardiograms |
US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
EP3079571A4 (en) | 2013-12-12 | 2017-08-02 | Alivecor, Inc. | Methods and systems for arrhythmia tracking and scoring |
WO2016036866A1 (en) | 2014-09-04 | 2016-03-10 | Corium International, Inc. | Microstructure array, methods of making, and methods of use |
USD759803S1 (en) | 2014-10-28 | 2016-06-21 | Highland Instruments, Inc. | Adjustable headpiece with anatomical markers |
GB2532044A (en) | 2014-11-06 | 2016-05-11 | Phagenesis Ltd | Catheter for recovery of dysphagia |
US11420047B2 (en) * | 2015-05-08 | 2022-08-23 | Athena E. Ivanoff | Wireless patch system for transdermal, transmucosal and dental electrical drug delivery |
EP3282933B1 (en) | 2015-05-13 | 2020-07-08 | Alivecor, Inc. | Discordance monitoring |
US10857093B2 (en) | 2015-06-29 | 2020-12-08 | Corium, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
US10716896B2 (en) | 2015-11-24 | 2020-07-21 | Insulet Corporation | Wearable automated medication delivery system |
CN109843149B (en) | 2016-07-22 | 2020-07-07 | 普罗秋斯数字健康公司 | Electromagnetic sensing and detection of ingestible event markers |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3991755A (en) * | 1973-07-27 | 1976-11-16 | Medicon, Inc. | Iontophoresis apparatus for applying local anesthetics |
US4141359A (en) * | 1976-08-16 | 1979-02-27 | University Of Utah | Epidermal iontophoresis device |
US4559037A (en) * | 1977-12-28 | 1985-12-17 | Siemens Aktiengesellschaft | Device for the pre-programmable infusion of liquids |
FR2420979A1 (en) * | 1978-03-28 | 1979-10-26 | Guillot Jacqueline | ELECTROCONDUCTOR MOLDING |
US4619653A (en) * | 1979-04-27 | 1986-10-28 | The Johns Hopkins University | Apparatus for detecting at least one predetermined condition and providing an informational signal in response thereto in a medication infusion system |
US4281664A (en) * | 1979-05-14 | 1981-08-04 | Medtronic, Inc. | Implantable telemetry transmission system for analog and digital data |
JPS5810066A (en) * | 1981-07-10 | 1983-01-20 | 株式会社アドバンス | Plaster structure for ion tofuorese |
US4494950A (en) * | 1982-01-19 | 1985-01-22 | The Johns Hopkins University | Plural module medication delivery system |
US4639244A (en) * | 1983-05-03 | 1987-01-27 | Nabil I. Rizk | Implantable electrophoretic pump for ionic drugs and associated methods |
US5224928A (en) * | 1983-08-18 | 1993-07-06 | Drug Delivery Systems Inc. | Mounting system for transdermal drug applicator |
US4541431A (en) * | 1984-09-20 | 1985-09-17 | Telectronics Pty. Ltd. | Use of telemetry coil to replace magnetically activated reed switch in implantable devices |
US4585652A (en) * | 1984-11-19 | 1986-04-29 | Regents Of The University Of Minnesota | Electrochemical controlled release drug delivery system |
US4819657A (en) * | 1985-04-12 | 1989-04-11 | Kvm Engineering, Inc. | Automatic allergy detection system |
US4942883A (en) * | 1987-09-29 | 1990-07-24 | Newman Martin H | Drug delivery device |
US5108363A (en) * | 1988-02-19 | 1992-04-28 | Gensia Pharmaceuticals, Inc. | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist |
US5011472A (en) * | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US5006108A (en) * | 1988-11-16 | 1991-04-09 | Noven Pharmaceuticals, Inc. | Apparatus for iontophoretic drug delivery |
US4981141A (en) * | 1989-02-15 | 1991-01-01 | Jacob Segalowitz | Wireless electrocardiographic monitoring system |
US5047007A (en) * | 1989-12-22 | 1991-09-10 | Medtronic, Inc. | Method and apparatus for pulsed iontophoretic drug delivery |
US5036861A (en) * | 1990-01-11 | 1991-08-06 | Sembrowich Walter L | Method and apparatus for non-invasively monitoring plasma glucose levels |
DE4028125A1 (en) * | 1990-01-17 | 1991-07-18 | Klimke Markus | Application plaster for regulated dosing of various pharmacons - uses electrical correct for percutaneous transport for local and systematic therapy |
US5160316A (en) * | 1990-09-10 | 1992-11-03 | Henley Julian L | Iontophoretic drug delivery apparatus |
US5170801A (en) * | 1990-10-02 | 1992-12-15 | Glaxo Inc. | Medical capsule device actuated by radio-frequency (rf) signal |
US5167626A (en) * | 1990-10-02 | 1992-12-01 | Glaxo Inc. | Medical capsule device actuated by radio-frequency (RF) signal |
US5059175A (en) * | 1990-10-09 | 1991-10-22 | University Of Utah Research Foundation | Implantable drug delivery system with piston actuation |
US5167625A (en) * | 1990-10-09 | 1992-12-01 | Sarcos Group | Multiple vesicle implantable drug delivery system |
US5224927A (en) * | 1990-11-01 | 1993-07-06 | Robert Tapper | Iontophoretic treatment system |
US5254081A (en) * | 1991-02-01 | 1993-10-19 | Empi, Inc. | Multiple site drug iontophoresis electronic device and method |
US5279607A (en) * | 1991-05-30 | 1994-01-18 | The State University Of New York | Telemetry capsule and process |
EP0526166A2 (en) * | 1991-07-29 | 1993-02-03 | Albert L. Dessertine | Patient compliance monitoring method and system |
US5169384A (en) * | 1991-08-16 | 1992-12-08 | Bosniak Stephen L | Apparatus for facilitating post-traumatic, post-surgical, and/or post-inflammatory healing of tissue |
US5246418A (en) * | 1991-12-17 | 1993-09-21 | Becton Dickinson And Company | Iontophresis system having features for reducing skin irritation |
FR2687028B1 (en) * | 1992-01-30 | 1994-04-29 | I2M Innovation Materiel Medica | DEVICE FOR REMOTE CONTROL OF THE INTENSITY DELIVERED BY A CURRENT GENERATOR WITH A HAND DIVE INTO A CONDUCTIVE LIQUID. |
US5309919A (en) * | 1992-03-02 | 1994-05-10 | Siemens Pacesetter, Inc. | Method and system for recording, reporting, and displaying the distribution of pacing events over time and for using same to optimize programming |
FR2695566B1 (en) * | 1992-09-16 | 1994-11-18 | Michel Gebert | Tissue electrophysiological stimulation device. |
US5380271A (en) * | 1992-09-24 | 1995-01-10 | Alza Corporation | Electrotransport agent delivery device and method |
-
1994
- 1994-10-31 US US08/332,322 patent/US5551953A/en not_active Expired - Lifetime
-
1995
- 1995-10-17 CA CA002198357A patent/CA2198357C/en not_active Expired - Fee Related
- 1995-10-17 DE DE69534722T patent/DE69534722T2/en not_active Expired - Lifetime
- 1995-10-17 KR KR1019970702841A patent/KR100382860B1/en not_active IP Right Cessation
- 1995-10-17 WO PCT/US1995/013218 patent/WO1996013302A1/en active IP Right Grant
- 1995-10-17 JP JP8514621A patent/JPH10507948A/en active Pending
- 1995-10-17 EP EP95936338A patent/EP0789603B1/en not_active Expired - Lifetime
- 1995-10-17 DK DK95936338T patent/DK0789603T3/en active
- 1995-10-17 AU AU38326/95A patent/AU691987B2/en not_active Ceased
- 1995-10-17 AT AT95936338T patent/ATE314113T1/en not_active IP Right Cessation
- 1995-10-17 ES ES95936338T patent/ES2250975T3/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2198357A1 (en) | 1996-05-09 |
ES2250975T3 (en) | 2006-04-16 |
EP0789603A1 (en) | 1997-08-20 |
WO1996013302A1 (en) | 1996-05-09 |
JPH10507948A (en) | 1998-08-04 |
DK0789603T3 (en) | 2006-03-06 |
DE69534722T2 (en) | 2006-08-31 |
KR970706863A (en) | 1997-12-01 |
KR100382860B1 (en) | 2003-08-06 |
AU3832695A (en) | 1996-05-23 |
MX9703227A (en) | 1997-07-31 |
EP0789603B1 (en) | 2005-12-28 |
ATE314113T1 (en) | 2006-01-15 |
US5551953A (en) | 1996-09-03 |
DE69534722D1 (en) | 2006-02-02 |
AU691987B2 (en) | 1998-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2198357C (en) | Electrotransport system with remote telemetry link | |
US6644321B1 (en) | Tactile feedback for indicating validity of communication link with an implantable medical device | |
US6445955B1 (en) | Miniature wireless transcutaneous electrical neuro or muscular-stimulation unit | |
US20180161576A1 (en) | Miniature implantable neurostimulator system for sciatic nerves and their branches | |
US6336047B1 (en) | Communication system between training sensor and electrodes of a defibrillator | |
US8391981B2 (en) | Cross-band communications in an implantable device | |
US6216038B1 (en) | Broadcast audible sound communication of programming change in an implantable medical device | |
US6450172B1 (en) | Broadcast audible sound communication from an implantable medical device | |
KR101248190B1 (en) | Body-patch type module, communication medical device including the same, and remote medical system using the same | |
US20020193844A1 (en) | Combination electrode-battery assembly for a miniature wireless transcutaneous electrical neuro or muscular-stimulation unit | |
EP0880936A3 (en) | Monitoring physical condition of a patient by telemetry | |
WO2012016165A1 (en) | Antenna for an implantable medical device | |
US7248926B2 (en) | Status indicator for implantable systems | |
EP1555934B1 (en) | Power saving uplink for biosensors | |
US8660659B2 (en) | Cross-band communications in an implantable device | |
MXPA97003227A (en) | Electrotransporte system with detelemetry link rem | |
JP2713149B2 (en) | Wireless in-vivo embedded receiver control system | |
WO2001074446A1 (en) | Implanted and programmable electrostimulator for stimulating organs and tissues of an organism | |
Jeutter | Principles and applications of biotelemetry | |
JPH0795644A (en) | Pocket beeper |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |